<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83075</article-id><article-id pub-id-type="doi">10.7554/eLife.83075</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-291173"><name><surname>Liu</surname><given-names>Cong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2852-8953</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292365"><name><surname>Schönke</surname><given-names>Milena</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292366"><name><surname>Spoorenberg</surname><given-names>Borah</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292367"><name><surname>Lambooij</surname><given-names>Joost M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292368"><name><surname>van der Zande</surname><given-names>Hendrik JP</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292369"><name><surname>Zhou</surname><given-names>Enchen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3739-4934</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292370"><name><surname>Tushuizen</surname><given-names>Maarten E</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-100297"><name><surname>Andreasson</surname><given-names>Anne-Christine</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8323-0658</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-292372"><name><surname>Park</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-292373"><name><surname>Oldham</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-292374"><name><surname>Uhrbom</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-100293"><name><surname>Ahlstedt</surname><given-names>Ingela</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-292375"><name><surname>Ikeda</surname><given-names>Yasuhiro</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-292376"><name><surname>Wallenius</surname><given-names>Kristina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3231-2733</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-202788"><name><surname>Peng</surname><given-names>Xiao-Rong</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-187811"><name><surname>Guigas</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-33258"><name><surname>Boon</surname><given-names>Mariëtte R</given-names></name><email>m.r.boon@lumc.nl</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-292377"><name><surname>Wang</surname><given-names>Yanan</given-names></name><email>y_wang@xjtufh.edu.cn</email><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-33257"><name><surname>Rensen</surname><given-names>Patrick CN</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8455-4988</contrib-id><email>p.c.n.rensen@lumc.nl</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05xvt9f17</institution-id><institution>Department of Medicine, Division of Endocrinology, Leiden University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05xvt9f17</institution-id><institution>Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05xvt9f17</institution-id><institution>Department of Parasitology, Leiden University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05xvt9f17</institution-id><institution>Department of Cell and Chemical Biology, Leiden University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05xvt9f17</institution-id><institution>Department of Gastroenterology and Hepatology, Leiden University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Leiden</named-content></addr-line><country>Netherlands</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wwrrg31</institution-id><institution>Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&amp;D, AstraZeneca</institution></institution-wrap><addr-line><named-content content-type="city">Gothenburg</named-content></addr-line><country>Sweden</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043cec594</institution-id><institution>Biologics Engineering and Targeted Delivery, Oncology R&amp;D, AstraZeneca</institution></institution-wrap><addr-line><named-content content-type="city">Gaithersburg</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043cec594</institution-id><institution>Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&amp;D, AstraZeneca</institution></institution-wrap><addr-line><named-content content-type="city">Gaithersburg</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zhmm22</institution-id><institution>Med-X institute, Center for Immunological and Metabolic Diseases, and Department of Endocrinology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University</institution></institution-wrap><addr-line><named-content content-type="city">Xi'an</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mistry</surname><given-names>Pramod</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>17</day><month>01</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83075</elocation-id><history><date date-type="received" iso-8601-date="2022-08-30"><day>30</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-01-16"><day>16</day><month>01</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-09-22"><day>22</day><month>09</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.09.20.508654"/></event></pub-history><permissions><copyright-statement>© 2023, Liu et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Liu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83075-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83075-figures-v2.pdf"/><abstract><p>Analogues of the hepatokine fibroblast growth factor 21 (FGF21) are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. Although their glucose-lowering and insulin-sensitizing effects have been largely unraveled, the mechanisms by which they alleviate liver injury have only been scarcely addressed. Here, we aimed to unveil the mechanisms underlying the protective effects of FGF21 on NASH using APOE*3-Leiden.CETP mice, a well-established model for human-like metabolic diseases. Liver-specific FGF21 overexpression was achieved in mice, followed by administration of a high-fat high-cholesterol diet for 23 weeks. FGF21 prevented hepatic lipotoxicity, accompanied by activation of thermogenic tissues and attenuation of adipose tissue inflammation, improvement of hyperglycemia and hypertriglyceridemia, and upregulation of hepatic programs involved in fatty acid oxidation and cholesterol removal. Furthermore, FGF21 inhibited hepatic inflammation, as evidenced by reduced Kupffer cell (KC) activation, diminished monocyte infiltration, and lowered accumulation of monocyte-derived macrophages. Moreover, FGF21 decreased lipid- and scar-associated macrophages, which correlated with less hepatic fibrosis as demonstrated by reduced collagen accumulation. Collectively, hepatic FGF21 overexpression limits hepatic lipotoxicity, inflammation, and fibrogenesis. Mechanistically, FGF21 blocks hepatic lipid influx and accumulation through combined endocrine and autocrine signaling, respectively, which prevents KC activation and lowers the presence of lipid- and scar-associated macrophages to inhibit fibrogenesis.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>High-calorie modern diets have contributed to growing rates of obesity-linked diseases. One such disease is non-alcoholic steatohepatitis or NASH for short, which affects about 5% of adults in the United States. The livers of people with this condition accumulate fat, become inflamed, and develop scar tissue. People with NASH are also at increased risk of developing liver cancer, type 2 diabetes, and heart disease. Currently, no drugs are available to treat the condition and prevent such severe complications.</p><p>Previous research has shown the liver produces a stress hormone, called FGF21, in response to fat accumulation. This hormone boosts fat burning and so helps to reduce excess fat in the liver. Drugs that mimic FGF21 have already been developed for type 2 diabetes. But so far, it was unclear if such drugs could also help reduce liver inflammation and scarring in patients with NASH.</p><p>Liu et al. show that increasing the production of FGF21 in mice with a NASH-like condition reduces fat accumulation, liver inflammation, and scarring. In the experiments, the researchers used gene therapy to ramp up FGF21 production in the livers of mice that develop obesity and a NASH-like condition when fed a high-fat diet for 23 weeks. Increasing FGF21 production prevented the mice from developing obesity while on the high fat diet by making the body burn more fat in the liver and brown fat tissue. The treatment also reduced inflammation and prevented scarring by reducing the number and activity of immune cells in the liver.</p><p>Increasing the production of the stress hormone FGF21 prevents diet-induced obesity and NASH in mice fed a high-fat diet. More studies are necessary to determine if using gene therapy to increase FGF21 may also cause weight loss and could reverse liver damage in mice that already have NASH. If this approach is effective in mice, it may be tested in humans, a process that may take several years. If human studies are successful, FGF21-boosting therapy might provide a new treatment approach for obesity or NASH.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>fibroblast growth factor 21</kwd><kwd>steatohepatitis</kwd><kwd>lipid/scar-associated macrophages</kwd><kwd>liver-adipose tissue crosstalk</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003092</institution-id><institution>Diabetes Fonds</institution></institution-wrap></funding-source><award-id>2015.81.1808</award-id><principal-award-recipient><name><surname>Boon</surname><given-names>Mariëtte R</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003246</institution-id><institution>Netherlands Organisation for Scientific Research</institution></institution-wrap></funding-source><award-id>VENI grant 91617027</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Yanan</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Chinese Scholarship Council</institution></institution-wrap></funding-source><award-id>CSC 201606010321</award-id><principal-award-recipient><name><surname>Zhou</surname><given-names>Enchen</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009708</institution-id><institution>Novo Nordisk Foundation</institution></institution-wrap></funding-source><award-id>NNF18OC0032394</award-id><principal-award-recipient><name><surname>Schönke</surname><given-names>Milena</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002996</institution-id><institution>Hartstichting</institution></institution-wrap></funding-source><award-id>The Netherlands Cardiovascular Research Initiative CVON-GENIUS-2</award-id><principal-award-recipient><name><surname>Rensen</surname><given-names>Patrick CN</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Fibroblast growth factor 21 blocks hepatic lipid influx and accumulation, prevents Kupffer cell activation, and inhibits the formation of hepatic lipid- and scar-associated macrophages, thereby likely inhibiting fibrogenesis in nonalcoholic steatohepatitis in humanized APOE*3-Leiden.CETP mice.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The liver is the nexus of many metabolic pathways, including those of glucose, fatty acids (FAs), and cholesterol. In health, these metabolites are distributed to peripheral tissues while preventing long-lasting accumulation in the liver. In a pathological state, however, lipids may accrue in the liver, thereby impairing liver function and carving the path toward the development of nonalcoholic fatty liver disease (NAFLD) (<xref ref-type="bibr" rid="bib13">Cusi, 2012</xref>). NAFLD is considered a spectrum of liver diseases ranging from liver steatosis, characterized by lipid accumulation in hepatocytes, to nonalcoholic steatohepatitis (NASH) with hepatic steatosis, lobular inflammation, hepatocyte ballooning, and varying degrees of fibrosis (<xref ref-type="bibr" rid="bib20">Friedman et al., 2018</xref>; <xref ref-type="bibr" rid="bib2">Arab et al., 2018</xref>). Patients diagnosed with NASH are predisposed to developing cirrhosis and hepatocellular carcinoma, among whom patients with severe liver fibrosis are at greatest risk of overall- and liver-related mortality (<xref ref-type="bibr" rid="bib55">Taylor et al., 2020</xref>). Despite this, there are currently no approved pharmaceutical therapeutics for NASH. Instead, lifestyle modifications remain the first-line treatment for NASH, although this is rarely attainable in the long term, and liver transplantation is still the sole intervention to treat the end-stage of NASH (<xref ref-type="bibr" rid="bib20">Friedman et al., 2018</xref>; <xref ref-type="bibr" rid="bib53">Stefan et al., 2019</xref>). Thus, there is an unmet need for therapeutic strategies that control the progression of NASH, in particular of liver fibrosis, and reverse the underlying pathophysiology.</p><p>Current hypotheses suggest that adipose tissue dysfunction and lipid spillover leads to hepatic lipotoxicity, and thereby the initiation of NASH (<xref ref-type="bibr" rid="bib42">Musso et al., 2009</xref>; <xref ref-type="bibr" rid="bib44">Neuschwander-Tetri, 2010</xref>), which further progresses through the inflammatory response triggered by hepatic lipotoxicity (<xref ref-type="bibr" rid="bib44">Neuschwander-Tetri, 2010</xref>). This inflammatory response and subsequent fibrogenesis are primarily initiated by liver macrophages (<xref ref-type="bibr" rid="bib54">Tacke, 2017</xref>). Hepatic macrophages mainly consist of embryonically derived macrophages, termed resident Kupffer cells (ResKCs), and monocyte-derived macrophages (MoDMacs) that are recruited from the circulation (<xref ref-type="bibr" rid="bib28">Krenkel and Tacke, 2017</xref>). In the steady state, ResKCs serve as sentinels for liver homeostasis. In NASH, liver injury caused by excess lipids and hepatocyte damage/death triggers ResKC activation, leading to pro-inflammatory cytokine and chemokine release (<xref ref-type="bibr" rid="bib56">Tran et al., 2020</xref>). This fosters the infiltration of newly recruited monocytes into the liver, which gives rise to various pro-inflammatory and pro-fibrotic macrophage subsets (<xref ref-type="bibr" rid="bib54">Tacke, 2017</xref>; <xref ref-type="bibr" rid="bib56">Tran et al., 2020</xref>). Interestingly, recent preclinical and clinical studies have reported that modulation of ResKC activation, monocyte recruitment, or macrophage differentiation, to some extent, can attenuate NASH (<xref ref-type="bibr" rid="bib54">Tacke, 2017</xref>; <xref ref-type="bibr" rid="bib29">Krenkel et al., 2018</xref>). In light of these findings, FGF21, a hepatokine with both lipid-lowering and anti-inflammatory properties (<xref ref-type="bibr" rid="bib39">Meng et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Guo et al., 2016</xref>), has been brought to the foreground as a promising potential therapeutic to treat NASH.</p><p>The specificity of FGF21 action for various metabolic tissues is determined by the FGF receptor (FGFR) which forms a heterodimer with the transmembrane co-receptor β-Klotho (KLB) (<xref ref-type="bibr" rid="bib17">Fisher and Maratos-Flier, 2016</xref>; <xref ref-type="bibr" rid="bib21">Geng et al., 2020</xref>). While the FGFR is ubiquitously expressed, KLB is primarily expressed in the liver and adipose tissue (<xref ref-type="bibr" rid="bib17">Fisher and Maratos-Flier, 2016</xref>; <xref ref-type="bibr" rid="bib21">Geng et al., 2020</xref>), therefore possibly limiting FGF21 action to these tissues. Physiologically, FGF21 is considered a stress-induced hormone whose levels rise in metabolically compromised states, such as obesity (<xref ref-type="bibr" rid="bib65">Zhang et al., 2008</xref>) and NASH (<xref ref-type="bibr" rid="bib5">Barb et al., 2019</xref>). The increased FGF21 in these pathologies is likely induced by an accumulation of lipids in the liver (<xref ref-type="bibr" rid="bib31">Li et al., 2010</xref>). As such, plasma FGF21 also positively correlates with the severity of steatohepatitis and fibrosis in patients with NASH (<xref ref-type="bibr" rid="bib5">Barb et al., 2019</xref>). Induction of FGF21 is thought to mediate a compensatory response to limit metabolic dysregulation (<xref ref-type="bibr" rid="bib18">Flippo and Potthoff, 2021</xref>), although this level is not sufficient. Interestingly, two-phase 2a clinical trials reported that pharmacological FGF21 treatment improves liver steatosis in NASH patients (<xref ref-type="bibr" rid="bib49">Sanyal et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Harrison et al., 2021</xref>). While an in vivo study testing the therapeutic potency of FGF21 in choline-deficient and high-fat diet-induced NASH has previously reported both anti-inflammatory and anti-fibrotic effects (<xref ref-type="bibr" rid="bib4">Bao et al., 2018</xref>), detailed mechanistic understanding is still lacking.</p><p>In the present study, we aimed to elucidate the mechanisms underlying FGF21-mediated improvement of NASH, in particular of steatohepatitis and fibrogenesis. To this end, we used APOE*3-Leiden.CETP mice, a well-established model for human cardiometabolic diseases. These mice exhibit human-like lipoprotein metabolism, develop hyperlipidemia, obesity, and inflammation when fed a high-fat high-cholesterol diet (HFCD), and develop fibrotic NASH closely resembling clinical features that accompany NASH in humans (<xref ref-type="bibr" rid="bib40">Morrison et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Liang et al., 2014</xref>). Moreover, these mice show human-like responses to both lipid-lowering and anti-inflammatory therapeutics during the development of metabolic syndrome (<xref ref-type="bibr" rid="bib58">van den Hoek et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">van der Hoorn et al., 2009</xref>; <xref ref-type="bibr" rid="bib32">Li et al., 2018</xref>; <xref ref-type="bibr" rid="bib15">Duivenvoorden et al., 2006</xref>). Here, we show that specific overexpression of FGF21 in the liver, resulting in increased circulating FGF21 levels, activates hepatic signaling associated with FA oxidation and cholesterol removal. In parallel, FGF21 activates thermogenic tissues and reduces adipose tissue inflammation, thereby protecting against adipose tissue dysfunction, hyperglycemia, and hypertriglyceridemia. As a consequence, FGF21 largely limits lipid accumulation in the liver and potently blocks hepatic KC activation and monocyte recruitment, thereby preventing the accumulation of pro-inflammatory macrophages in the liver. In addition, FGF21 reduced the number of pro-fibrotic macrophages in the injured liver, potentially explaining why FGF21 counteracts all features of NASH, including hepatic steatosis, inflammation, and fibrogenesis.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Liver-specific FGF21 overexpression increases circulating FGF21 levels and protects against HFCD-induced body fat mass gain</title><p>We aimed to elucidate the underlying mechanisms of FGF21-mediated hepatoprotective effects on NASH, by using APOE*3-Leiden.CETP mice fed with an HFCD, a model that induces all stages of NASH in a human-like fashion and recapitulates the ultrastructural changes observed in NASH patients (<xref ref-type="bibr" rid="bib40">Morrison et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Liang et al., 2014</xref>). Since the liver is the main contributor to circulating FGF21 (<xref ref-type="bibr" rid="bib17">Fisher and Maratos-Flier, 2016</xref>), we employed an adeno-associated virus 8 (AAV8) vector expressing codon-optimized murine <italic>Fgf21</italic> to induce liver-specific FGF21 overexpression in APOE*3-Leiden.CETP mice. Mice treated with either AAV8-<italic>Fgf21</italic> or AAV8-null as controls were fed with an HFCD for 23 weeks (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We confirmed liver-specific FGF21 overexpression by a large increase in codon-optimized <italic>Fgf21</italic> expression in the liver but not in adipose tissue (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), resulting in high circulating FGF21 levels that persisted throughout the study (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). In addition, we observed that HFCD feeding increased hepatic endogenous <italic>Fgf21</italic> expression (+184%), which, however, was prevented by AAV8-<italic>Fgf21</italic> administration (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Furthermore, by performing a Student’s t test between the low-fat low-cholesterol diet (LFCD) and HFCD groups, we did observe that as compared to the LFCD group, HFCD feeding increased plasma FGF21 levels at week 4 (+52%) and week 23 (+383%) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). These results are in agreement with previous findings showing that FGF21 is a stress-induced hepatokine whose levels increase in metabolically compromised states, such as obesity (<xref ref-type="bibr" rid="bib65">Zhang et al., 2008</xref>) and NAFLD (<xref ref-type="bibr" rid="bib5">Barb et al., 2019</xref>). HFCD progressively and profoundly increased body weight over the experimental period, accompanied by increased white adipose tissue (WAT) and brown adipose tissue (BAT) weights relative to those of LFCD-fed mice (<xref ref-type="fig" rid="fig1">Figure 1D,E</xref>). In favorable contrast, FGF21 reduced body weight in the first 3 weeks, after which body weight stabilized and remained lower than that of LFCD- and HFCD-fed mice by the end of the study (−18% and −35%, respectively; <xref ref-type="fig" rid="fig1">Figure 1D</xref>). Concomitantly, FGF21 decreased weights of gonadal WAT (gWAT; −67%), subcutaneous WAT (sWAT; −55%), interscapular BAT (iBAT; −41%), and subscapular BAT (−41%) to levels comparable to those observed in LFCD-fed mice (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). These findings thus highlight the potent effects of FGF21 on preventing fat mass gain under NASH-inducing dietary conditions.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Liver-specific FGF21 overexpression increases circulating FGF21 levels and protects against HFCD-induced body fat mass gain.</title><p>(<bold>A</bold>) Experimental setup. (<bold>B</bold>) At week 23, codon-optimized FGF21 mRNA expression in the liver and gWAT was quantified (n=16 –18), and endogenous <italic>Fgf21</italic> expression in the liver was also measured (n=16–18). (<bold>C</bold>) Plasma FGF21 levels were measured before (at week –1; pooled samples, n=6 per group) and after (at week 4, pooled samples, n=6 per group; week 23, n=12–16 per group) AAV8-<italic>Fgf21</italic> administration. (<bold>D</bold>) Body weight was monitored throughout the experimental period (n=17–18). (<bold>E</bold>) At week 23, brown adipose tissue (BAT) and white adipose tissue (WAT) depots were isolated and weighed (n=18). Data are shown as mean ± SEM. Differences were assessed using one-way ANOVA followed by a Tukey’s post test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, compared with the LFCD group. <sup>###</sup>p&lt;0.001, compared with the HFCD group. (<bold>C</bold>) Differences between the LFCD and HFCD groups were assessed using Student’s t test. <sup>$$</sup>p&lt;0.01, compared the LFCD group. AAV8, adeno-associated virus 8; FGF21, fibroblast growth factor 21; gWAT, gonadal WAT; HFCD, high-fat and high-cholesterol diet; iBAT, interscapular BAT; LFCD, low-fat and low-cholesterol diet; sBAT, subscapular BAT; sWAT, subcutaneous WAT.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Liver-specific FGF21 overexpression increases circulating FGF21 levels and protects against HFCD-induced body fat mass gain.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig1-v2.tif"/></fig></sec><sec id="s2-2"><title>FGF21 protects against HFCD-induced adipose tissue dysfunction</title><p>The profound fat mass-lowering effects of liver-derived FGF21 prompted us to examine its role in adipose tissue function. Since we and others have previously shown that FGF21 activates thermogenic adipose tissues (<xref ref-type="bibr" rid="bib50">Schlein et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Liu et al., 2022</xref>), we first performed histological analyses of BAT and sWAT, the adipose tissue that is most prone to browning (<xref ref-type="bibr" rid="bib67">Zhang et al., 2018</xref>). We observed that FGF21 prevented the HFCD-induced lipid overload in BAT (−66%) and increased uncoupling protein-1 (UCP-1) expression compared with both the LFCD- and HFCD-fed groups (+15% and +26%, respectively) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). In sWAT, FGF21 prevented HFCD-induced adipocyte hypertrophy (−41%), and increased the UCP-1 content (+94%) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Among the adipose tissue depots, gWAT is most prone to diet-induced inflammation, and surgical removal of inflamed gWAT attenuates NASH in obese mice (<xref ref-type="bibr" rid="bib41">Mulder et al., 2016</xref>). Similar to sWAT, FGF21 protected against HFCD-induced adipocyte enlargement (−52%) in gWAT and in addition fully prevented the formation of crown-like structures (CLSs; −93%) (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). In agreement with these findings, FGF21 suppressed the HFCD-induced expression of adhesion G protein-coupled receptor E1 (<italic>Adgre1</italic>; −56%), encoding the macrophage surface marker F4/80, in addition to decreased expression of the pro-inflammatory mediators tumor necrosis factor α (<italic>Tnfa</italic>; −60%), interleukin-1β (<italic>Il1b</italic>; −50%), and monocyte attractant chemokine C–C motif ligand 2 (<italic>Ccl2</italic>; −60%) (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Besides, FGF21 tended to upregulate <italic>Klb</italic> (+33%) and <italic>Fgfr1</italic> (+30%) expression compared to HFCD-fed mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Moreover, consistent with the critical role of adiponectin in mediating the therapeutic benefits of FGF21 in adipose tissue (<xref ref-type="bibr" rid="bib4">Bao et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Lin et al., 2013</xref>), FGF21 increased plasma adiponectin levels compared to both LFCD- and HFCD-fed mice (+93% and +133%, respectively; <xref ref-type="fig" rid="fig2">Figure 2E</xref>). These combined findings thus indicate that FGF21 prevents HFCD-induced adipose tissue dysfunction during NASH development.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Fibroblast growth factor 21 (FGF21) protects against high-fat high-cholesterol diet (HFCD)-induced adipose tissue dysfunction.</title><p>(<bold>A</bold>) In interscapular brown adipose tissue (iBAT), the lipid content and expression of uncoupling protein-1 (UCP-1) were quantified after hematoxylin-eosin (H&amp;E) staining and UCP-1 immunostaining, respectively. (<bold>B</bold>) In subcutaneous white adipose tissue (sWAT), the adipocyte enlargement was assessed by H&amp;E staining, and the tissue browning was evaluated by UCP-1 immunostaining. (<bold>C</bold>) In gonadal white adipose tissue (gWAT), the adipocyte hypertrophy was detected, and the number of crown-like structures (CLSs) was assessed, and (<bold>D</bold>) mRNA expression of pro-inflammatory markers was quantified. (<bold>E</bold>) Plasma adiponectin concentration in fasted blood plasma was measured at week 22. (<bold>A</bold>–<bold>D</bold>) n=14–18 per group; (<bold>E</bold>) n=10 per group. Differences were assessed using one-way ANOVA followed by a Tukey’s post test. *p&lt;0.05, ***p&lt;0.001, compared with the low-fat low-cholesterol diet (LFCD) group. <sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01, <sup>###</sup>p&lt;0.001, compared with the HFCD group. <italic>Adgre1</italic>, adhesion G protein-coupled receptor E1; <italic>Tnfa</italic>, tumor necrosis factor α; <italic>Il1b</italic>, interleukin-1β; <italic>Ccl2</italic>, chemokine C–C motif ligand 2.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Fibroblast growth factor 21 (FGF21) protects against high-fat high-cholesterol diet (HFCD)-induced adipose tissue dysfunction.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Liver-specific fibroblast growth factor 21 (FGF21) overexpression tends to upregulate mRNA expression of FGF21 receptor 1 (FGFR1) and co-receptor β-Klotho (KLB) in white adipose tissue (WAT).</title><p>The mRNA expression of KLB and FGFR1 in gonadal WAT (gWAT). Data are shown as mean ± SEM (n=16–18 per group). Differences were assessed using one-way ANOVA followed by a Tukey’s post test.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Liver-specific fibroblast growth factor 21 (FGF21) overexpression tends to upregulate mRNA expression of FGF21 receptor 1 (FGFR1) and co-receptor β-Klotho (KLB) in white adipose tissue (WAT).</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig2-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig2-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>FGF21 alleviates HFCD-induced hyperglycemia and hypertriglyceridemia</title><p>We next examined whether FGF21 confers its glucose- and lipid-lowering effects during NASH development. While HFCD induced hyperglycemia as compared to LFCD, FGF21 normalized fasting plasma glucose compared to LFCD, which was accompanied by lower glucose excursion after an intraperitoneal glucose tolerance test (IPGTT) (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>). In addition, FGF21 normalized the plasma insulin and Homeostatic Model Assessment for Insulin Resistance index (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), indicating that FGF21 restores insulin sensitivity to that observed in LFCD-fed mice. FGF21 did not prevent the HFCD-induced increase of plasma total cholesterol (TC) levels (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), nor the distribution of cholesterol over the various lipoproteins (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Nonetheless, FGF21 strongly and consistently reduced fasting plasma triglyceride (TG) levels throughout the experimental period compared with LFCD- and HFCD-fed mice (−67% and −58%; at week 22), which was specific for very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). In addition, an oral lipid tolerance test revealed that FGF21 prevented HFCD-induced lipid intolerance (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Taken together, FGF21 prevents the HFCD-induced increase in circulating glucose and reduces circulating TG levels beyond those observed in LFCD-fed mice.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Fibroblast growth factor 21 (FGF21) alleviates high-fat high-cholesterol diet (HFCD)-induced hyperglycemia and hypertriglyceridemia.</title><p>(<bold>A</bold>) Fasting plasma glucose levels were measured during the experimental period. (<bold>B</bold>) At week 16, an intraperitoneal glucose tolerance test (IPGTT) was initiated. (<bold>B</bold>) The area under the curve (AUC) of plasma glucose during the IPGTT and (<bold>C</bold>) plasma insulin concentration in response to the IPGTT was determined at the indicated timepoints. (<bold>C</bold>) Homeostasis model assessment of insulin resistance (HOMA-IR) was determined from fasting glucose and insulin levels. (<bold>D</bold>) Fasting plasma triglyceride (TG) levels were measured throughout the study. The distribution of triglyceride over lipoproteins was determined (pooled samples; n=5 per group) from plasma of week 22. (<bold>E</bold>) At week 20, an oral lipid tolerance test (OLTT) was initiated, and AUC of plasma TG during the OLTT was calculated. (<bold>A and D</bold>) n=14–18 per group; (<bold>B–C</bold>) n=7–8 per group; (<bold>E</bold>) n=6–9 per group. Data are shown as mean ± SEM. Differences were assessed using one-way ANOVA followed by a Tukey’s post test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, compared with the low-fat low-cholesterol diet (LFCD) group. <sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01, <sup>###</sup>p&lt;0.001, compared with the HFCD group.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Fibroblast growth factor 21 (FGF21) alleviates high-fat high-cholesterol diet (HFCD)-induced hyperglycemia and hypertriglyceridemia.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>High-fat high-cholesterol diet (HFCD) increases fasting cholesterol levels.</title><p>(<bold>A</bold>) Fasting plasma total cholesterol (TC) levels were measured over a 23-week intervention period (n=14–18 per group), and (<bold>B</bold>) the distribution of the cholesterol over circulating lipoproteins was assessed at week 22 (pooled samples; n=18 per group). Data are shown as mean ± SEM. Differences were assessed using one-way ANOVA followed by a Tukey’s post test. ***p&lt;0.001, compared with the low-fat low-cholesterol diet (LFCD) group. VLDL, very low-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>High-fat high-cholesterol diet (HFCD) increases fasting cholesterol levels.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig3-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>FGF21 protects against HFCD-induced hepatic steatosis, inflammation, and fibrogenesis</title><p>Then, we investigated the effects of FGF21 on liver steatosis, inflammation, and fibrosis. FGF21 not only prevented HFCD-induced liver weight gain (−58%), but even reduced liver weight to a level lower than that of LFCD-fed mice (−40%; <xref ref-type="fig" rid="fig4">Figure 4A,F</xref>). Moreover, FGF21 abolished the HFCD-induced increase in steatosis, lobular inflammation, and hepatocellular ballooning (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,B</xref>). Therefore, FGF21 completely prevented the HFCD-induced large increase in the NAFLD activity score (−74%; <xref ref-type="fig" rid="fig4">Figure 4C,F</xref>). Furthermore, FGF21 prevented collagen accumulation in the liver as assessed by Picrosirius Red staining (−58%; <xref ref-type="fig" rid="fig4">Figure 4D,F</xref>). We then measured hepatic concentration of hydroxyproline, a major constituent of collagen and thus a marker of extracellular matrix accumulation. In line with the hepatic collagen content, HFCD feeding increased the hepatic hydroxyproline content, which was prevented by FGF21 (−49%; <xref ref-type="fig" rid="fig4">Figure 4E</xref>). Taken together, our data demonstrate that FGF21 protects against HFCD-induced hepatosteatosis, steatohepatitis, as well as fibrogenesis.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Fibroblast growth factor 21 (FGF21) protects against high-fat high-cholesterol diet (HFCD)-induced hepatic steatosis, inflammation, and fibrosis.</title><p>(<bold>A</bold>) At week 23, liver weight was determined, and (<bold>B</bold>) scoring of histological features of steatosis, lobular inflammation, and ballooning as well as (<bold>C</bold>) nonalcoholic fatty liver disease (NAFLD) activity was evaluated by hematoxylin-eosin (H&amp;E) staining. (<bold>D</bold>) Liver fibrosis was assessed by Picrosirius Red (PSR) staining, and (<bold>E</bold>) hepatic hydroxyproline levels were determined. (<bold>F</bold>) Representative macroscopic, H&amp;E, and PSR pictures are shown. Data are shown as mean ± SEM (n=16–18 per group). Differences were assessed using one-way ANOVA followed by a Tukey’s post test. *p&lt;0.05; **p&lt;0.01, ***p&lt;0.001, compared with the low-fat low-cholesterol diet (LFCD) group. <sup>##</sup>p&lt;0.01; <sup>###</sup>p&lt;0.001, compared with the HFCD group.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Fibroblast growth factor 21 (FGF21) protects against high-fat high-cholesterol diet (HFCD)-induced hepatic steatosis, inflammation, and fibrosis.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Fibroblast growth factor 21 (FGF21) abolishes high-fat high-cholesterol diet (HFCD)-induced increase of hepatic lipid-positive area and the number of inflammatory foci.</title><p>At week 23, (<bold>A</bold>) hepatic lipid droplet content and (<bold>B</bold>) inflammatory foci numbers were assessed by hematoxylin-eosin (H&amp;E) staining. Data are shown as mean ± SEM (n=18 per group). Differences were assessed using one-way ANOVA followed by a Tukey’s post test. **p&lt;0.01, ***p&lt;0.001, compared with the low-fat low-cholesterol diet (LFCD) group. <sup>#</sup>p&lt;0.01 <sup>###</sup>p&lt;0.001, compared with the HFCD group.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Fibroblast growth factor 21 (FGF21) abolishes high-fat high cholesterol diet (HFCD)-induced increase of hepatic lipid-positive area and the number of inflammatory foci.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig4-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>FGF21 abolishes liver lipotoxicity, accompanied by activation of hepatic signaling involved in FA oxidation and cholesterol removal</title><p>In the context of NASH, pro-inflammatory responses and fibrogenesis occur when hepatocytes are injured by lipotoxicity (<xref ref-type="bibr" rid="bib44">Neuschwander-Tetri, 2010</xref>; <xref ref-type="bibr" rid="bib37">Machado and Diehl, 2016</xref>). Indeed, 23 weeks of HFCD feeding promoted aberrant accumulation of TG as well as TC in the liver (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). In agreement with the data presented in <xref ref-type="fig" rid="fig4">Figure 4</xref>, FGF21 abrogated the HFCD-induced increase in hepatic TG levels (−62%) and tended to decrease hepatic TC levels (−22%), resulting in smaller lipid droplets (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). In addition to reduced lipid overflow from WAT, we reasoned that FGF21 may also directly act on the liver to prevent HFCD-induced liver lipotoxicity. In agreement, compared to both LFCD- and HFCD-fed mice, FGF21 profoundly upregulated the expression of <italic>Klb</italic> (+150% and +223%), <italic>Fgfr1</italic> (+57% and +79%), <italic>Fgfr2</italic> (+97% and +77%), and <italic>Fgfr4</italic> (+53% and +67%) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). We next quantified the hepatic expression of key genes involved in FA and cholesterol handling. FGF21 did not attenuate the HFCD-induced increased expression of FA translocase cluster of differentiation 36 (C<italic>d36</italic>) (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>). In favorable contrast, compared to both LFCD- and HFCD-fed mice, FGF21 did increase the expression of carnitine palmitoyl transferase 1α (<italic>Cpt1a</italic>, +66% and +53%), peroxisome proliferator-activated receptor α (<italic>Ppara</italic>, +67% and +53%) and peroxisome proliferator-activated receptor γ coactivator 1α (<italic>Pgc1a</italic>; +188% and +225%), all of those genes being key players involved in FA oxidation (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Moreover, compared to LFCD- and HFCD-fed mice, FGF21 increased the expression of apolipoprotein B (<italic>Apob</italic>, +26% and +38%), which is involved in VLDL secretion (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>). Furthermore, FGF21 upregulated the expression of ATP-binding cassette transporter G member 5 (<italic>Abcg5</italic>; sevenfold and twofold), crucial for biliary secretion of neutral sterols (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), increased the expression of cholesterol 7α-hydroxylase (<italic>Cyp7a1</italic>; +94% and +109%), a key gene involved in the classic bile acid synthesis pathway (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), and restored the expression of sterol 27-hydroxylase (+38%), involved in the alternative bile acid pathway (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Considering that bile acid synthesis is a major pathway for hepatic cholesterol disposal (<xref ref-type="bibr" rid="bib57">Tu et al., 2000</xref>), FGF21 likely regulates bile acid metabolism to prevent HFCD-induced cholesterol accumulation in the liver. Collectively, our data indicate that FGF21 increases the hepatic expression of key genes involved in β-oxidation and cholesterol removal, which together with reduced lipid overload from WAT may explain FGF21-induced alleviation of liver lipotoxicity under NASH-inducing dietary conditions.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Fibroblast growth factor 21 (FGF21) abolishes liver lipotoxicity, accompanied by activation of hepatic signaling involved in fatty acid (FA) oxidation and cholesterol removal.</title><p>(<bold>A</bold>) Triglyceride (TG), total cholesterol (TC), and phospholipid (PL) levels were determined in the liver (n=18 per group), and representative Oil Red O (ORO) pictures are shown. (<bold>B</bold>) The relative mRNA expression of genes involved in fatty acid oxidation and (<bold>C and D</bold>) cholesterol removal (n=15–18 per group) were determined in the liver. Data are shown as mean ± SEM. Differences were assessed using one-way ANOVA followed by a Tukey’s post test. **p&lt;0.01, ***p&lt;0.001, compared with the low-fat low-cholesterol diet (LFCD) group. <sup>###</sup>p&lt;0.001, compared with the high-fat high-cholesterol diet (HFCD) group. <italic>Abcg5</italic>, ATP-binding cassette transporter G member 5; <italic>Cpt1a</italic>, carnitine palmitoyl transferase 1α; <italic>Cyp7a1</italic>, cholesterol 7α-hydroxylase; <italic>Cyp8b1</italic>, sterol 12α-hydroxylase; <italic>Cyp27a1</italic>, sterol 27-hydroxylase; <italic>Pgc1a</italic>, peroxisome proliferator-activated receptor gamma coactivator 1α; <italic>Ppara</italic>, peroxisome proliferator-activated receptor α.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Fibroblast growth factor 21 (FGF21) abolishes liver lipotoxicity, accompanied by activation of hepatic signaling involved in fatty acid (FA) oxidation and cholesterol removal.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Liver-specific fibroblast growth factor 21 (FGF21) overexpression upregulates hepatic mRNA expression of FGF21 receptors (FGFRs) and co-receptor β-Klotho (KLB).</title><p>The mRNA levels of KLB and FGFRs in the liver. Data are shown as mean ± SEM (n=14–18 per group). Differences were assessed using one-way ANOVA followed by a Tukey’s post test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, compared with the low-fat low-cholesterol diet (LFCD) group. <sup>##</sup>p&lt;0.01, <sup>###</sup>p&lt;0.001, compared with the high-fat high-cholesterol diet (HFCD) group.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Liver-specific fibroblast growth factor 21 (FGF21) overexpression upregulates hepatic mRNA expression of FGF21 receptors (FGFRs) and co-receptor β-Klotho (KLB).</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Fibroblast growth factor 21 (FGF21) increases apolipoprotein B mRNA (<italic>Apob</italic>) expression in the liver.</title><p>At end of the study, hepatic expression of genes involved in (<bold>A</bold>) fatty acid uptake and (<bold>B</bold>) very low-density lipoprotein (VLDL) production was quantified (n=15–18 per group). Data are shown as mean ± SEM. Differences were assessed using one-way ANOVA followed by a Tukey’s post test. ***p&lt;0.001, compared with the low-fat low-cholesterol diet (LFCD) group. <sup>###</sup>p&lt;0.001, compared with the high-fat high-cholesterol diet (HFCD) group. <italic>Apob</italic>, apolipoprotein B<italic>; Cd36</italic>, cluster of differentiation 36; <italic>Mttp</italic>, microsomal triglyceride transfer protein.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Fibroblast growth factor 21 (FGF21) increases apolipoprotein B mRNA (<italic>Apob</italic>) expression in the liver.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig5-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig5-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>FGF21 prevents activation of various KC subsets</title><p>Then, we performed an in-depth phenotyping of hepatic immune cells using spectral flow cytometry. For this, we developed a panel that identifies most major immune cell subsets (for gating strategy see <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). As compared to LFCD, HFCD tended to reduce total CD45<sup>+</sup> leukocytes, which were increased by FGF21 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Combining conventional gating and dimension reduction analysis through uniform manifold approximation and projection allowed to identify FGF21-induced changes in cell subset abundance (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). FGF21 prevented HFCD-induced loss of eosinophils, neutrophils and B cells, and increased numbers of dendritic cells and T cells compared with those observed in both LFCD- and HFCD-fed mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). More importantly, FGF21 increased the number of total KCs compared with that of both LFCD- and HFCD-fed mice (+63% and +156; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>), attenuated HFCD-induced monocyte recruitment (−18%), and tended to repress the HFCD-induced increase in hepatic MoDMacs (−42%; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Fibroblast growth factor 21 (FGF21) modulates hepatic macrophage pool and protects against COL1A1 accumulation, as predicted by the reduction of CD36<sup>hi</sup> Kupffer cells (KCs) and CD9<sup>hi</sup> KCs.</title><p>(<bold>A</bold>) Uniform manifold approximation and projection for dimension reduction (UMAP) of immune cell subsets from livers after 23 weeks of intervention. (<bold>B</bold>) The number of resident KCs (ResKCs), the proportion of CD11c<sup>+</sup> ResKCs, and the expression of CD36 and CD9 in ResKCs were quantified. (<bold>C</bold>) The amount of monocyte-derived KCs (MoKCs) was assessed, the percentage of CD11c<sup>+</sup> MoKCs was determined, the CD36 and CD9 expression levels in MoKCs were quantified. (<bold>D</bold>) Hepatic inflammation was evaluated by pro-inflammatory gene expression and the formation of crown-like structures (CLSs) within the liver. The mRNA expression of liver fibrogenesis markers was quantified, and the protein expression of collagen type 1α 1 (COL1A1) was determined. (<bold>E</bold>) The expression of CD36 in ResKCs, and the expression of CD9 and CD36 in MoKCs were plotted against COL1A1-positive area in the liver. (<bold>F</bold>) Mechanistic model. Data are shown as mean ± SEM (<bold>A–B and E</bold>, n=4–5 per group; <bold>D</bold>, n=16–18 per group). Linear regression analyses were performed. Differences were assessed using one-way ANOVA followed by a Fisher’s LSD test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, compared with the low-fat low-cholesterol diet (LFCD) group. <sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01, <sup>###</sup>p&lt;0.001, compared with the high-fat high-cholesterol diet (HFCD) group. <italic>Acta2</italic>, actin α2; <italic>Ctgf</italic>, connective tissue growth factor; FA, fatty acid; <italic>Tgfb1</italic>, transforming growth factor-β.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Fibroblast growth factor 21 (FGF21) modulates hepatic macrophage pool and protects against COL1A1 accumulation, as predicted by the reduction of CD36<sup>hi</sup> Kupffer cells (KCs) and CD9<sup>hi</sup> KCs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Fibroblast growth factor 21 (FGF21) modulates the hepatic immune cell pool.</title><p>(<bold>A</bold>) Flow cytometry gating strategy. (<bold>B</bold>) After 23 weeks of treatment, CD45<sup>+</sup> cells were isolated from the liver, and the number of CD45<sup>+</sup> cells, eosinophils, neutrophils, B cells, dendritic cells (DCs), T cells, natural killer (NK) cells, total Kupffer cells (KCs), Ly6C<sup>hi</sup> monocytes, and monocyte-derived macrophages (MoDMacs) was assessed. Data are shown as mean ± SEM (n=4–5 per group). Differences were assessed using one-way ANOVA followed by a Fisher’s LSD test. *p&lt;0.05, **p&lt;0.01, compared with the low-fat low-cholesterol diet (LFCD) group. <sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01, compared with the high-fat high-cholesterol diet (HFCD) group.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Fibroblast growth factor 21 (FGF21) modulates the hepatic immune cell pool.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig6-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>CD36<sup>hi</sup> resident Kupffer cells (ResKCs) as well as CD36<sup>hi</sup>/CD9<sup>hi</sup> monocyte-derived KCs (MoKCs) positively correlate with nonalcoholic fatty liver disease (NAFLD) activity score and liver fibrosis.</title><p>NAFLD activity scores and liver hydroxyproline levels were plotted against the expression of (<bold>A</bold>) CD9 and (<bold>B</bold>) CD36 in ResKCs as well as (<bold>C</bold>) CD9 and (<bold>D</bold>) CD36 in MoKCs. (<bold>E</bold>) Hepatic expression of collagen type 1α 1 (COL1A1) was plotted against the expression of CD9 in ResKCs. Linear regression analyses were performed. Data are represented as mean ± SEM (n=5 per group).</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>CD36<sup>hi</sup> resident Kupffer cells (ResKCs) as well as CD36<sup>hi</sup>/CD9<sup>hi</sup> monocyte-derived KCs (MoKCs) positively correlate with nonalcoholic fatty liver disease (NAFLD) activity score and liver fibrosis.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83075-fig6-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-fig6-figsupp2-v2.tif"/></fig></fig-group><p>During the development of NASH, MoDMacs can gradually seed in KC pool by acquiring ResKCs identity and replacing the dying ResKCs (<xref ref-type="bibr" rid="bib56">Tran et al., 2020</xref>). These recruited MoKCs can have both detrimental and supportive roles, contributing to increase in pathology during fibrosis onset, but hastening recovery when the damage-evoking agent is attenuated/removed (<xref ref-type="bibr" rid="bib52">Seidman et al., 2020</xref>). In light of this, we assessed the abundance and phenotype of ResKCs and monocyte-derived KCs (MoKCs). We observed that FGF21 completely abolished the HFCD-induced reduction of the number of ResKCs (+319%) and potently protected against HFCD-induced ResKC activation as shown by decreased proportion of CD11c<sup>+</sup> ResKCs (−53%; <xref ref-type="fig" rid="fig6">Figure 6B</xref>). FGF21 also completely abolished the HFCD-induced upregulation of CD36 in ResKCs, to levels that are even lower than those in LFCD-fed mice (−88% vs. LFCD; −94% vs. HFCD; <xref ref-type="fig" rid="fig6">Figure 6B</xref>). In addition, FGF21 increased the number of MoKCs compared with that of both LFCD- and HFCD-fed mice (+92% and +123%), and prevented the HFCD-induced increase in the abundance of CD11c<sup>+</sup> MoKCs (−42%) (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Strikingly, compared to both LFCD- and HFCD-fed mice, FGF21 downregulated CD9 (−32% and −49%) and CD36 (−98% and −100%) in MoKCs (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Furthermore, FGF21 profoundly repressed HFCD-induced upregulation of hepatic <italic>Tnfa</italic> (−37%), <italic>Il1b</italic> (−41%), and <italic>Ccl2</italic> (−54%) expression to levels comparable to those in LFCD-fed mice (<xref ref-type="fig" rid="fig6">Figure 6D</xref>), which is in line with the observation that FGF21 prevents KC activation. Given that CD36<sup>hi</sup> ResKCs and CD36<sup>hi</sup>/ CD9<sup>hi</sup> MoKCs are involved in the formation of hepatic CLSs (<xref ref-type="bibr" rid="bib56">Tran et al., 2020</xref>; <xref ref-type="bibr" rid="bib52">Seidman et al., 2020</xref>; <xref ref-type="bibr" rid="bib8">Blériot et al., 2021</xref>; <xref ref-type="bibr" rid="bib14">Daemen et al., 2021</xref>), we next assessed CLSs and observed that FGF21 completely prevented the HFCD-induced formation of CLSs in the liver (−93%; <xref ref-type="fig" rid="fig6">Figure 6D</xref>). These data demonstrate that FGF21 inhibits the activation of ResKCs and MoKCs and prevents the accumulation of CD36<sup>hi</sup> ResKCs and CD36<sup>hi</sup>/CD9<sup>hi</sup> MoKCs under dietary conditions that result in NASH, which likely contribute to the beneficial effects of FGF21 on hepatic inflammation and fibrosis.</p></sec><sec id="s2-7"><title>FGF21 protects against COL1A1 accumulation, as predicted by the reduction of CD36<sup>hi</sup> KCs and CD9<sup>hi</sup> KCs</title><p>To further evaluate whether FGF21-induced reductions of lipid-associated macrophages (i.e., CD36<sup>hi</sup> ResKCs and CD36<sup>hi</sup> MoKCs) (<xref ref-type="bibr" rid="bib8">Blériot et al., 2021</xref>) and scar-associated macrophages (i.e., CD9<sup>hi</sup> MoKCs) (<xref ref-type="bibr" rid="bib46">Ramachandran et al., 2019</xref>) are implicated in fibrogenesis, we performed multiple univariate regression analyses. These revealed that both NAFLD activity and liver fibrosis were associated with both CD36<sup>hi</sup> ResKCs, CD36<sup>hi</sup> MoKCs, and CD9<sup>hi</sup> MoKCs (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A-D</xref>), indicating that FGF21 likely improves liver fibrosis by reducing these lipid- and scar-associated macrophages. To further understand the underlying mechanisms by which FGF21 prevents liver fibrosis, we measured hepatic expression of key genes involved in fibrogenesis (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). FGF21 tended to decrease the expression of connective tissue growth factor (<italic>Ctgf</italic>; −27%), a major fibrogenic factor, and normalized the HFCD-induced increased expression of its downstream target collagen type Iα 1 (<italic>Col1a1</italic>; −61%; <xref ref-type="fig" rid="fig6">Figure 6D</xref>). This finding was confirmed by immunohistochemistry, revealing that FGF21 reduced hepatic COL1A1 accumulation (−46%; <xref ref-type="fig" rid="fig6">Figure 6D</xref>). Furthermore, univariate regression analysis revealed that COL1A1 expression is predicted by CD36<sup>hi</sup> ResKCs, CD36<sup>hi</sup> MoKCs, and CD9<sup>hi</sup> MoKCs (<xref ref-type="fig" rid="fig6">Figure 6E</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2E</xref>). Taken together, these data indicate that FGF21 reduces lipid- and scar-associated macrophages to inhibit COL1A1 synthesis and prevent fibrogenesis.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Several FGF21 analogues are currently being evaluated in clinical trials for the treatment of NASH (<xref ref-type="bibr" rid="bib49">Sanyal et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Harrison et al., 2021</xref>). While the protective effect of pharmacological intervention with long-acting FGF21 on human liver steatosis has been uncovered (<xref ref-type="bibr" rid="bib49">Sanyal et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Harrison et al., 2021</xref>; <xref ref-type="bibr" rid="bib1">Aggarwal et al., 2022</xref>), mechanisms underlying attenuated steatosis as well all the anti-inflammatory and anti-fibrotic effects of FGF21 on NASH are still largely unexplored. Therefore, we set out to elucidate mechanisms by which FGF21 beneficially modulates these various aspects of NASH in HFCD-fed APOE*3-Leiden.CETP mice, a well-established model for diet-induced NASH (<xref ref-type="bibr" rid="bib40">Morrison et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Liang et al., 2014</xref>). Based on our findings, we propose that FGF21 attenuates liver lipotoxicity via endocrine signaling to adipose tissue to induce thermogenesis, thereby preventing adipose tissue dysfunction to reduce lipid overflow to the liver, as well as autocrine signaling to the liver to increase FA oxidation and cholesterol removal. In addition, FGF21 prevents KC activation, monocyte recruitment, and the formation of lipid- and scar-associated macrophages, thereby likely inhibiting collagen accumulation and alleviating liver fibrogenesis.</p><p>Hepatic lipotoxicity is one of the major risk factors determining the progression of liver steatosis into NASH, as shown in multiple clinical studies with obese patients (<xref ref-type="bibr" rid="bib10">Bril et al., 2017</xref>; <xref ref-type="bibr" rid="bib3">Armstrong et al., 2016</xref>; <xref ref-type="bibr" rid="bib47">Ratziu et al., 2021</xref>). By feeding APOE*3-Leiden.CETP mice a diet rich in fat and cholesterol, we mimicked a situation in which a positive energy balance induces many aspects of the metabolic syndrome, including insulin resistance, obesity with increased fat accumulation, and hepatic lipotoxicity indicated by hepatomegaly with aberrant accumulation of TG as well as TC. Hepatic lipotoxicity likely results from lipid overflow from insulin-resistant adipose tissue toward the liver in combination with hepatic insulin resistance that prevents insulin-stimulated outflow of lipids (<xref ref-type="bibr" rid="bib64">Zarei et al., 2020</xref>). Within this dietary context, we applied a single administration of an AAV8 vector encoding codon-optimized FGF21, which resulted in liver-specific FGF21 overexpression. Since the codon-optimized FGF21 mitigates the poor pharmacokinetic properties of native FGF21, including its short plasma half-life (0.5–2 hr) by reducing proteolytic degradation (<xref ref-type="bibr" rid="bib64">Zarei et al., 2020</xref>), an elevated level of circulating FGF21 was reached throughout the dietary intervention period. By this strategy, we mimicked the situation in which circulating FGF21 predominantly derives from the liver (<xref ref-type="bibr" rid="bib45">Nishimura et al., 2000</xref>). Indeed, circulating FGF21 correlates well with the hepatic expression of FGF21 (<xref ref-type="bibr" rid="bib38">Markan et al., 2014</xref>). Interestingly, hepatic expression of FGF21 fully prevented the diet-induced increase in liver weight, liver lipids (i.e., TG and TC), and steatosis score.</p><p>These lipotoxicity-protective effects of FGF21 can partially be explained by endocrine effects of liver-derived FGF21 on adipose tissue, which besides the liver has high expression of KLB, the co-receptor of the FGFR (<xref ref-type="bibr" rid="bib17">Fisher and Maratos-Flier, 2016</xref>; <xref ref-type="bibr" rid="bib21">Geng et al., 2020</xref>). Indeed, FGF21 fully prevented the HFCD-induced increase in weights of WAT and BAT, with decreased lipid accumulation in these adipose tissue depots as well as induction of BAT activation and WAT browning. These data imply that FGF21 induces thermogenesis which increases energy expenditure, consistent with the thermogenic responses observed for recombinant FGF21 in C57BL/6 mice fed with an obesogenic diet (<xref ref-type="bibr" rid="bib50">Schlein et al., 2016</xref>). Likewise, by using APOE*3-Leiden.CETP mice, we previously reported that FGF21 treatment highly increased energy expenditure without affecting food intake (<xref ref-type="bibr" rid="bib35">Liu et al., 2022</xref>). Activation of thermogenic tissues by classical β-adrenergic receptor largely increases the uptake of circulating lipoprotein-derived FAs by BAT and beige WAT (<xref ref-type="bibr" rid="bib7">Berbée et al., 2015</xref>), which we recently also demonstrated for recombinant FGF21 (<xref ref-type="bibr" rid="bib35">Liu et al., 2022</xref>). This can thus at least partly explain the marked TG-lowering effect of FGF21 observed in the current study. Thermogenic activation also increases the uptake and combustion of glucose, although the glucose-lowering and insulin-sensitizing effects of FGF21 can also be explained by attenuated WAT inflammation in combination with increased adiponectin expression as well as improved liver insulin sensitivity (<xref ref-type="bibr" rid="bib35">Liu et al., 2022</xref>; <xref ref-type="bibr" rid="bib34">Lin et al., 2013</xref>; <xref ref-type="bibr" rid="bib62">Yang et al., 2018</xref>).</p><p>Besides endocrine FGF21 signaling in adipose tissue, liver lipotoxicity is likely further prevented by autocrine FGF21 signaling. Indeed, we showed that liver-specific FGF21 overexpression increased hepatic expression of genes involved in FA oxidation (<italic>Cpt1a</italic>, <italic>Ppara</italic>, <italic>Pgc1a</italic>), biliary cholesterol secretion (<italic>Abcg5</italic>), bile acids synthesis (<italic>Cyp7a1</italic>), and VLDL production (<italic>Apob</italic>). Of note, these observations are in line with previous reports showing increased FA oxidation (<xref ref-type="bibr" rid="bib16">Fisher et al., 2014</xref>) and upregulated <italic>Abcg5</italic> (<xref ref-type="bibr" rid="bib26">Keinicke et al., 2020</xref>), <italic>Cyp7a1</italic> (<xref ref-type="bibr" rid="bib26">Keinicke et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">Zhang et al., 2017</xref>), and <italic>Apob</italic> (<xref ref-type="bibr" rid="bib35">Liu et al., 2022</xref>) in the liver upon FGF21 treatment. Altogether, the marked protective effects of FGF21 on HFCD-induced hepatic lipotoxicity likely results from combined endocrine and autocrine signaling, leading to reduced lipid influx from adipose tissue to the liver coupled to the activation of hepatic FA oxidation and cholesterol elimination pathways. Our observations may likely explain the recent clinical findings that treatment with FGF21 analogues in patients with NASH not only reduced hepatic steatosis (<xref ref-type="bibr" rid="bib49">Sanyal et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Harrison et al., 2021</xref>) but also increased hepatic bile acid synthesis and further promoted cholesterol removal, lowering the risk for further hepatic lipotoxicity (<xref ref-type="bibr" rid="bib36">Luo et al., 2022</xref>).</p><p>While NASH is initiated by hepatic lipotoxicity, NASH progression is mainly driven by impaired KC homeostasis and subsequent liver inflammation (<xref ref-type="bibr" rid="bib11">Cai et al., 2019</xref>). Therefore, we investigated in depth the inflammatory response in the liver through a combination of immunohistochemistry, flow cytometry, and gene expression analyses. HFCD feeding induced an array of inflammatory effects, including increased lobular inflammation, hepatocyte ballooning and NAFLD activity scores, as well as increased inflammatory foci and CLSs, accompanied by a reduction in ResKCs with a relative increase in CD11c<sup>+</sup> ResKCs, and an increase in MoDMacs and CD11c<sup>+</sup> MoKCs. These observations are likely explained by lipotoxicity-related damage to ResKCs, and release of TNFα, IL-1β, and MCP-1 (<italic>Ccl2</italic>), both activating various downstream pro-inflammatory mediators and promoting monocyte recruitment to remodel the KC pool (<xref ref-type="bibr" rid="bib56">Tran et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Remmerie et al., 2020</xref>) and further exacerbating hepatic inflammation (<xref ref-type="bibr" rid="bib56">Tran et al., 2020</xref>; <xref ref-type="bibr" rid="bib8">Blériot et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">Cai et al., 2019</xref>; <xref ref-type="bibr" rid="bib51">Schwabe et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">Yu et al., 2019</xref>). Importantly, FGF21 prevented most of these HFCD-induced inflammatory responses, as it normalized lobular inflammation, hepatocyte ballooning and NAFLD activity scores and CLSs, and reduced pro-inflammatory activation of various KC subsets.</p><p>Fibrosis has been identified as the most important predictor of prognosis in NAFLD patients, and therefore a main target in experimental pharmacological approaches (<xref ref-type="bibr" rid="bib24">Heyens et al., 2021</xref>). HFCD feeding during 23 weeks induced early signs of fibrosis, as evident from an increased <italic>Col1a1</italic> expression and COL1A1 content, accompanied by an increased content of the hydroxyproline. Importantly, FGF21 blocked liver fibrogenesis, and decreased the hydroxyproline content. These alterations were accompanied with reductions in lipid-associated macrophages (i.e., CD36<sup>hi</sup> ResKCs/MoKCs) (<xref ref-type="bibr" rid="bib8">Blériot et al., 2021</xref>) and scar-associated macrophages (i.e., CD9<sup>hi</sup> MoKCs) (<xref ref-type="bibr" rid="bib46">Ramachandran et al., 2019</xref>). In fact, when analyzing the mouse groups together, CD36<sup>hi</sup> ResKCs/MoKCs and CD9<sup>hi</sup> MoKCs positively correlated with liver fibrosis as reflected by hydroxyproline content and COL1A-positive area, suggesting that these lipid- and scar-associated macrophages are involved in fibrogenesis in our model. Indeed, high numbers of CD9<sup>hi</sup> macrophages have been found in fibrotic regions of the liver (<xref ref-type="bibr" rid="bib52">Seidman et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Daemen et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Ramachandran et al., 2019</xref>; <xref ref-type="bibr" rid="bib48">Remmerie et al., 2020</xref>), and these cells are able to prime quiescent primary murine hepatic stellate cells to upregulate the expression of fibrillar collagen through CTGF (<xref ref-type="bibr" rid="bib46">Ramachandran et al., 2019</xref>), thereby promoting and exacerbating liver fibrosis. Therefore, we speculate that FGF21 protects against early liver fibrosis likely through preventing the accumulation of CD36<sup>hi</sup>/CD9<sup>hi</sup> KCs, thereby inhibiting activation of hepatic stellate cells to produce collagen.</p><p>This study is not without limitations. In this work, we used a gene therapy approach to examine the effects of liver-derived FGF21 on NASH based on the use of a single injection of an AAV8 vector encoding codon-optimized murine FGF21. Although AAV8 is hepatocyte trophic, we have not excluded potential contribution of other hepatic cells to total FGF21 expression. Also, while AAV8-<italic>Fgf21</italic> was non-toxic, sustained supra-pharmacological plasma levels of FGF21 were achieved, which do not necessarily reflect effects of current pharmacological strategies with long-acting FGF21. Interestingly, AAV-mediated gene therapy has already been tested in the clinic for life-threatening diseases such as hemophilia B, and has demonstrated stable expression of factor IX following AAV-mediated delivery (<xref ref-type="bibr" rid="bib43">Nathwani et al., 2018</xref>). Therefore, it is reasonable to speculate that liver-targeted gene therapy as an approach to induce stable overexpression of FGF21 may ultimately have potential to reach to the clinic.</p><p>In conclusion, hepatic overexpression of FGF21 in APOE*3-Leiden.CETP mice limits diet-induced hepatic lipotoxicity, inflammation, and fibrogenesis. Through a combination of endocrine and autocrine signaling, FGF21 reduces hepatic lipid influx and accumulation, respectively. This results in reduced macrophage activation and monocyte recruitment with less presence of lipid- and scar-associated macrophages, limiting activation of hepatic stellate cells to produce collagen (for graphic summary, see <xref ref-type="fig" rid="fig6">Figure 6F</xref>). As such, our studies provide a mechanistic explanation for the hepatoprotective effects of FGF21 analogues in recent clinical trials including reduction in steatosis (<xref ref-type="bibr" rid="bib49">Sanyal et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Harrison et al., 2021</xref>; <xref ref-type="bibr" rid="bib36">Luo et al., 2022</xref>) as well as the fibrotic marker N-terminal type III collagen pro-peptide (<xref ref-type="bibr" rid="bib49">Sanyal et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Harrison et al., 2021</xref>), and further highlight the potential of FGF21 for clinical implementation as a therapeutic in the treatment of advanced NASH.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><p>Please see Appendix 1 for a detailed description of all experimental procedures.</p><sec id="s4-1"><title>Animals and treatments</title><p>Male APOE*3-Leiden.CETP mice (on a C57BL/6J background) were generated as previously described (<xref ref-type="bibr" rid="bib61">Westerterp et al., 2006</xref>). Mice at the age of 10–12 weeks were group-housed (2–4 mice per cage) under standard conditions (22°C, 12/12 hr light/dark cycle) with ad libitum access to water and an LFCD (Standard Rodent Diet 801203, Special Diets Services, UK), unless indicated otherwise. Then, based on body weight and 4 hr (9.00–13.00) fasted plasma glucose, TG and TC levels, these mice were randomized into three treatment groups (n=18 per group), after which they received either AAV8-<italic>Fgf21</italic>, a liver-tropic AAV8 capsid vector expressing codon-optimized murine <italic>Fgf21</italic> under the control of a liver-specific apolipoprotein E (<italic>Apoe</italic>)/alpha-1-antitrypsin (<italic>Aat</italic>) promoter (HFCD+FGF21 group; 2×10<sup>10</sup> genome copies per mouse), or with the same genome copy number of AAV8-null (HFCD and LFCD groups) via a single intravenous injection. After 1 week of recovery, mice in the HFCD+FGF21 and HFCD groups were switched to an HFCD (60% fat and 1% cholesterol; C1090-60, Altromin, Germany) and maintained on the diet for 23 weeks, at which APOE*3-Leiden.CETP mice have developed both steatosis, hepatic inflammation and early fibrosis (<xref ref-type="bibr" rid="bib40">Morrison et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Hui et al., 2018</xref>). An IPGTT (n=8 per group) and an oral lipid tolerance test (n=10 per group) were performed at week 16 and week 20, respectively. Flow cytometry (n=5 per group) was conducted at week 23.</p></sec><sec id="s4-2"><title>Statistics</title><p>Comparisons among three groups were analyzed using one-way ANOVA followed by a Tukey’s post test, unless indicated otherwise. Data are presented as mean ± SEM, and a p-value of less than 0.05 was considered statistically significant. All statistical analyses were performed with GraphPad Prism 9.01 for Windows (GraphPad Software Inc, California, CA, USA).</p></sec><sec id="s4-3"><title>Study approval</title><p>All animal experiments were carried out according to the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals, and were approved by the National Committee for Animal Experiments (Protocol No. AVD1160020173305) and by the Ethics Committee on Animal Care and Experimentation of the Leiden University Medical Center (Protocol No. PE.18.034.041).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>employee of AstraZeneca</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Supervision, Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Formal analysis, Validation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con17"><p>Funding acquisition, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Validation, Investigation, Methodology, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal experiments were carried out according to the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals, and were approved by the National Committee for Animal Experiments (Protocol No. AVD1160020173305) and by the Ethics Committee on Animal Care and Experimentation of the Leiden University Medical Center (Protocol No. PE.18.034.041).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83075-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the Dutch Diabetes Research Foundation (2015.81.1808 to MRB); the Netherlands Organisation for Scientific Research-NWO (VENI grant 91617027 to YW); Chinese Scholarship Council grants (CSC 201606010321 to EZ); the Novo Nordisk Foundation (NNF18OC0032394 to MS); and the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation (CVON-GENIUS-2 to PCNR). The authors also thank TCM Streefland, ACM Pronk, RA Lalai, and HCM Sips from Department of Medicine, the Division of Endocrinology, Leiden University Medical Center for technical assistance.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>P</given-names></name><name><surname>Noureddin</surname><given-names>M</given-names></name><name><surname>Harrison</surname><given-names>S</given-names></name><name><surname>Jeannin</surname><given-names>S</given-names></name><name><surname>Alkhouri</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials</article-title><source>Expert Opinion on Investigational Drugs</source><volume>31</volume><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1080/13543784.2022.2032640</pub-id><pub-id pub-id-type="pmid">35060815</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arab</surname><given-names>JP</given-names></name><name><surname>Arrese</surname><given-names>M</given-names></name><name><surname>Trauner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Recent insights into the pathogenesis of nonalcoholic fatty liver disease</article-title><source>Annual Review of Pathology</source><volume>13</volume><fpage>321</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-020117-043617</pub-id><pub-id pub-id-type="pmid">29414249</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>MJ</given-names></name><name><surname>Hull</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>K</given-names></name><name><surname>Barton</surname><given-names>D</given-names></name><name><surname>Hazlehurst</surname><given-names>JM</given-names></name><name><surname>Gathercole</surname><given-names>LL</given-names></name><name><surname>Nasiri</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Gough</surname><given-names>SC</given-names></name><name><surname>Newsome</surname><given-names>PN</given-names></name><name><surname>Tomlinson</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Glucagon-Like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis</article-title><source>Journal of Hepatology</source><volume>64</volume><fpage>399</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.08.038</pub-id><pub-id pub-id-type="pmid">26394161</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>LC</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Yao</surname><given-names>WB</given-names></name><name><surname>Gao</surname><given-names>XD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway</article-title><source>British Journal of Pharmacology</source><volume>175</volume><fpage>3379</fpage><lpage>3393</lpage><pub-id pub-id-type="doi">10.1111/bph.14383</pub-id><pub-id pub-id-type="pmid">29859019</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barb</surname><given-names>D</given-names></name><name><surname>Bril</surname><given-names>F</given-names></name><name><surname>Kalavalapalli</surname><given-names>S</given-names></name><name><surname>Cusi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>104</volume><fpage>3327</fpage><lpage>3336</lpage><pub-id pub-id-type="doi">10.1210/jc.2018-02414</pub-id><pub-id pub-id-type="pmid">30848827</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedossa</surname><given-names>P</given-names></name><name><surname>Poitou</surname><given-names>C</given-names></name><name><surname>Veyrie</surname><given-names>N</given-names></name><name><surname>Bouillot</surname><given-names>JL</given-names></name><name><surname>Basdevant</surname><given-names>A</given-names></name><name><surname>Paradis</surname><given-names>V</given-names></name><name><surname>Tordjman</surname><given-names>J</given-names></name><name><surname>Clement</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients</article-title><source>Hepatology</source><volume>56</volume><fpage>1751</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1002/hep.25889</pub-id><pub-id pub-id-type="pmid">22707395</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berbée</surname><given-names>JFP</given-names></name><name><surname>Boon</surname><given-names>MR</given-names></name><name><surname>Khedoe</surname><given-names>P</given-names></name><name><surname>Bartelt</surname><given-names>A</given-names></name><name><surname>Schlein</surname><given-names>C</given-names></name><name><surname>Worthmann</surname><given-names>A</given-names></name><name><surname>Kooijman</surname><given-names>S</given-names></name><name><surname>Hoeke</surname><given-names>G</given-names></name><name><surname>Mol</surname><given-names>IM</given-names></name><name><surname>John</surname><given-names>C</given-names></name><name><surname>Jung</surname><given-names>C</given-names></name><name><surname>Vazirpanah</surname><given-names>N</given-names></name><name><surname>Brouwers</surname><given-names>LPJ</given-names></name><name><surname>Gordts</surname><given-names>P</given-names></name><name><surname>Esko</surname><given-names>JD</given-names></name><name><surname>Hiemstra</surname><given-names>PS</given-names></name><name><surname>Havekes</surname><given-names>LM</given-names></name><name><surname>Scheja</surname><given-names>L</given-names></name><name><surname>Heeren</surname><given-names>J</given-names></name><name><surname>Rensen</surname><given-names>PCN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6356</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7356</pub-id><pub-id pub-id-type="pmid">25754609</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blériot</surname><given-names>C</given-names></name><name><surname>Barreby</surname><given-names>E</given-names></name><name><surname>Dunsmore</surname><given-names>G</given-names></name><name><surname>Ballaire</surname><given-names>R</given-names></name><name><surname>Chakarov</surname><given-names>S</given-names></name><name><surname>Ficht</surname><given-names>X</given-names></name><name><surname>De Simone</surname><given-names>G</given-names></name><name><surname>Andreata</surname><given-names>F</given-names></name><name><surname>Fumagalli</surname><given-names>V</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Wan</surname><given-names>G</given-names></name><name><surname>Gessain</surname><given-names>G</given-names></name><name><surname>Khalilnezhad</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>XM</given-names></name><name><surname>Ang</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Morgantini</surname><given-names>C</given-names></name><name><surname>Azzimato</surname><given-names>V</given-names></name><name><surname>Kong</surname><given-names>WT</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Pai</surname><given-names>R</given-names></name><name><surname>Lum</surname><given-names>J</given-names></name><name><surname>Shihui</surname><given-names>F</given-names></name><name><surname>Low</surname><given-names>I</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Malleret</surname><given-names>B</given-names></name><name><surname>Kairi</surname><given-names>MFM</given-names></name><name><surname>Balachander</surname><given-names>A</given-names></name><name><surname>Cexus</surname><given-names>O</given-names></name><name><surname>Larbi</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Newell</surname><given-names>EW</given-names></name><name><surname>Ng</surname><given-names>LG</given-names></name><name><surname>Phoo</surname><given-names>WW</given-names></name><name><surname>Sobota</surname><given-names>RM</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Howland</surname><given-names>SW</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Bajenoff</surname><given-names>M</given-names></name><name><surname>Yvan-Charvet</surname><given-names>L</given-names></name><name><surname>Venteclef</surname><given-names>N</given-names></name><name><surname>Iannacone</surname><given-names>M</given-names></name><name><surname>Aouadi</surname><given-names>M</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A subset of Kupffer cells regulates metabolism through the expression of CD36</article-title><source>Immunity</source><volume>54</volume><fpage>2101</fpage><lpage>2116</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.08.006</pub-id><pub-id pub-id-type="pmid">34469775</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bligh</surname><given-names>EG</given-names></name><name><surname>Dyer</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="1959">1959</year><article-title>A rapid method of total lipid extraction and purification</article-title><source>Canadian Journal of Biochemistry and Physiology</source><volume>37</volume><fpage>911</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1139/o59-099</pub-id><pub-id pub-id-type="pmid">13671378</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bril</surname><given-names>F</given-names></name><name><surname>Barb</surname><given-names>D</given-names></name><name><surname>Portillo-Sanchez</surname><given-names>P</given-names></name><name><surname>Biernacki</surname><given-names>D</given-names></name><name><surname>Lomonaco</surname><given-names>R</given-names></name><name><surname>Suman</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>MH</given-names></name><name><surname>Budd</surname><given-names>JT</given-names></name><name><surname>Lupi</surname><given-names>ME</given-names></name><name><surname>Cusi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease</article-title><source>Hepatology</source><volume>65</volume><fpage>1132</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1002/hep.28985</pub-id><pub-id pub-id-type="pmid">27981615</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>XJ</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The role of innate immune cells in nonalcoholic steatohepatitis</article-title><source>Hepatology</source><volume>70</volume><fpage>1026</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1002/hep.30506</pub-id><pub-id pub-id-type="pmid">30653691</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardiff</surname><given-names>RD</given-names></name><name><surname>Miller</surname><given-names>CH</given-names></name><name><surname>Munn</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Manual hematoxylin and eosin staining of mouse tissue sections</article-title><source>Cold Spring Harbor Protocols</source><volume>2014</volume><fpage>655</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1101/pdb.prot073411</pub-id><pub-id pub-id-type="pmid">24890205</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications</article-title><source>Gastroenterology</source><volume>142</volume><fpage>711</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2012.02.003</pub-id><pub-id pub-id-type="pmid">22326434</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daemen</surname><given-names>S</given-names></name><name><surname>Gainullina</surname><given-names>A</given-names></name><name><surname>Kalugotla</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Chan</surname><given-names>MM</given-names></name><name><surname>Beals</surname><given-names>JW</given-names></name><name><surname>Liss</surname><given-names>KH</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name><name><surname>Feldstein</surname><given-names>AE</given-names></name><name><surname>Finck</surname><given-names>BN</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Schilling</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH</article-title><source>Cell Reports</source><volume>34</volume><elocation-id>108626</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108626</pub-id><pub-id pub-id-type="pmid">33440159</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duivenvoorden</surname><given-names>I</given-names></name><name><surname>Voshol</surname><given-names>PJ</given-names></name><name><surname>Rensen</surname><given-names>PCN</given-names></name><name><surname>van Duyvenvoorde</surname><given-names>W</given-names></name><name><surname>Romijn</surname><given-names>JA</given-names></name><name><surname>Emeis</surname><given-names>JJ</given-names></name><name><surname>Havekes</surname><given-names>LM</given-names></name><name><surname>Nieuwenhuizen</surname><given-names>WF</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3Leiden mice</article-title><source>The American Journal of Clinical Nutrition</source><volume>84</volume><fpage>312</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1093/ajcn/84.1.312</pub-id><pub-id pub-id-type="pmid">16895877</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>FM</given-names></name><name><surname>Chui</surname><given-names>PC</given-names></name><name><surname>Nasser</surname><given-names>IA</given-names></name><name><surname>Popov</surname><given-names>Y</given-names></name><name><surname>Cunniff</surname><given-names>JC</given-names></name><name><surname>Lundasen</surname><given-names>T</given-names></name><name><surname>Kharitonenkov</surname><given-names>A</given-names></name><name><surname>Schuppan</surname><given-names>D</given-names></name><name><surname>Flier</surname><given-names>JS</given-names></name><name><surname>Maratos-Flier</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets</article-title><source>Gastroenterology</source><volume>147</volume><fpage>1073</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2014.07.044</pub-id><pub-id pub-id-type="pmid">25083607</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>FM</given-names></name><name><surname>Maratos-Flier</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Understanding the physiology of FGF21</article-title><source>Annual Review of Physiology</source><volume>78</volume><fpage>223</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-021115-105339</pub-id><pub-id pub-id-type="pmid">26654352</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flippo</surname><given-names>KH</given-names></name><name><surname>Potthoff</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Metabolic messengers: FGF21</article-title><source>Nature Metabolism</source><volume>3</volume><fpage>309</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1038/s42255-021-00354-2</pub-id><pub-id pub-id-type="pmid">33758421</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraulob</surname><given-names>JC</given-names></name><name><surname>Ogg-Diamantino</surname><given-names>R</given-names></name><name><surname>Fernandes-Santos</surname><given-names>C</given-names></name><name><surname>Aguila</surname><given-names>MB</given-names></name><name><surname>Mandarim-de-Lacerda</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet</article-title><source>Journal of Clinical Biochemistry and Nutrition</source><volume>46</volume><fpage>212</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.3164/jcbn.09-83</pub-id><pub-id pub-id-type="pmid">20490316</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>SL</given-names></name><name><surname>Neuschwander-Tetri</surname><given-names>BA</given-names></name><name><surname>Rinella</surname><given-names>M</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanisms of NAFLD development and therapeutic strategies</article-title><source>Nature Medicine</source><volume>24</volume><fpage>908</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0104-9</pub-id><pub-id pub-id-type="pmid">29967350</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>L</given-names></name><name><surname>Lam</surname><given-names>KSL</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic</article-title><source>Nature Reviews. Endocrinology</source><volume>16</volume><fpage>654</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1038/s41574-020-0386-0</pub-id><pub-id pub-id-type="pmid">32764725</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fibroblast growth factor 21 potentially inhibits microrna-33 expression to affect macrophage actions</article-title><source>Lipids in Health and Disease</source><volume>15</volume><elocation-id>208</elocation-id><pub-id pub-id-type="doi">10.1186/s12944-016-0381-6</pub-id><pub-id pub-id-type="pmid">27905947</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>SA</given-names></name><name><surname>Ruane</surname><given-names>PJ</given-names></name><name><surname>Freilich</surname><given-names>BL</given-names></name><name><surname>Neff</surname><given-names>G</given-names></name><name><surname>Patil</surname><given-names>R</given-names></name><name><surname>Behling</surname><given-names>CA</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Fong</surname><given-names>E</given-names></name><name><surname>de Temple</surname><given-names>B</given-names></name><name><surname>Tillman</surname><given-names>EJ</given-names></name><name><surname>Rolph</surname><given-names>TP</given-names></name><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Yale</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2A trial</article-title><source>Nature Medicine</source><volume>27</volume><fpage>1262</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01425-3</pub-id><pub-id pub-id-type="pmid">34239138</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heyens</surname><given-names>LJM</given-names></name><name><surname>Busschots</surname><given-names>D</given-names></name><name><surname>Koek</surname><given-names>GH</given-names></name><name><surname>Robaeys</surname><given-names>G</given-names></name><name><surname>Francque</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment</article-title><source>Frontiers in Medicine</source><volume>8</volume><elocation-id>615978</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2021.615978</pub-id><pub-id pub-id-type="pmid">33937277</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>ST</given-names></name><name><surname>Kurt</surname><given-names>Z</given-names></name><name><surname>Tuominen</surname><given-names>I</given-names></name><name><surname>Norheim</surname><given-names>F</given-names></name><name><surname>C Davis</surname><given-names>R</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Dirks</surname><given-names>DL</given-names></name><name><surname>Magyar</surname><given-names>CE</given-names></name><name><surname>French</surname><given-names>SW</given-names></name><name><surname>Chella Krishnan</surname><given-names>K</given-names></name><name><surname>Sabir</surname><given-names>S</given-names></name><name><surname>Campos-Pérez</surname><given-names>F</given-names></name><name><surname>Méndez-Sánchez</surname><given-names>N</given-names></name><name><surname>Macías-Kauffer</surname><given-names>L</given-names></name><name><surname>León-Mimila</surname><given-names>P</given-names></name><name><surname>Canizales-Quinteros</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Beaven</surname><given-names>SW</given-names></name><name><surname>Huertas-Vazquez</surname><given-names>A</given-names></name><name><surname>Lusis</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The genetic architecture of diet-induced hepatic fibrosis in mice</article-title><source>Hepatology</source><volume>68</volume><fpage>2182</fpage><lpage>2196</lpage><pub-id pub-id-type="doi">10.1002/hep.30113</pub-id><pub-id pub-id-type="pmid">29907965</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keinicke</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Mentzel</surname><given-names>CMJ</given-names></name><name><surname>Fredholm</surname><given-names>M</given-names></name><name><surname>John</surname><given-names>LM</given-names></name><name><surname>Andersen</surname><given-names>B</given-names></name><name><surname>Raun</surname><given-names>K</given-names></name><name><surname>Kjaergaard</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Fgf21 regulates hepatic metabolic pathways to improve steatosis and inflammation</article-title><source>Endocrine Connections</source><volume>9</volume><fpage>755</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1530/EC-20-0152</pub-id><pub-id pub-id-type="pmid">32688339</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kooijman</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Parlevliet</surname><given-names>ET</given-names></name><name><surname>Boon</surname><given-names>MR</given-names></name><name><surname>Edelschaap</surname><given-names>D</given-names></name><name><surname>Snaterse</surname><given-names>G</given-names></name><name><surname>Pijl</surname><given-names>H</given-names></name><name><surname>Romijn</surname><given-names>JA</given-names></name><name><surname>Rensen</surname><given-names>PCN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice</article-title><source>Diabetologia</source><volume>58</volume><fpage>2637</fpage><lpage>2646</lpage><pub-id pub-id-type="doi">10.1007/s00125-015-3727-0</pub-id><pub-id pub-id-type="pmid">26254578</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krenkel</surname><given-names>O</given-names></name><name><surname>Tacke</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Liver macrophages in tissue homeostasis and disease</article-title><source>Nature Reviews. Immunology</source><volume>17</volume><fpage>306</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.11</pub-id><pub-id pub-id-type="pmid">28317925</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krenkel</surname><given-names>O</given-names></name><name><surname>Puengel</surname><given-names>T</given-names></name><name><surname>Govaere</surname><given-names>O</given-names></name><name><surname>Abdallah</surname><given-names>AT</given-names></name><name><surname>Mossanen</surname><given-names>JC</given-names></name><name><surname>Kohlhepp</surname><given-names>M</given-names></name><name><surname>Liepelt</surname><given-names>A</given-names></name><name><surname>Lefebvre</surname><given-names>E</given-names></name><name><surname>Luedde</surname><given-names>T</given-names></name><name><surname>Hellerbrand</surname><given-names>C</given-names></name><name><surname>Weiskirchen</surname><given-names>R</given-names></name><name><surname>Longerich</surname><given-names>T</given-names></name><name><surname>Costa</surname><given-names>IG</given-names></name><name><surname>Anstee</surname><given-names>QM</given-names></name><name><surname>Trautwein</surname><given-names>C</given-names></name><name><surname>Tacke</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis</article-title><source>Hepatology</source><volume>67</volume><fpage>1270</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1002/hep.29544</pub-id><pub-id pub-id-type="pmid">28940700</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanthier</surname><given-names>N</given-names></name><name><surname>Molendi-Coste</surname><given-names>O</given-names></name><name><surname>Horsmans</surname><given-names>Y</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Cani</surname><given-names>PD</given-names></name><name><surname>Leclercq</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Kupffer cell activation is a causal factor for hepatic insulin resistance</article-title><source>American Journal of Physiology. Gastrointestinal and Liver Physiology</source><volume>298</volume><fpage>G107</fpage><lpage>G116</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00391.2009</pub-id><pub-id pub-id-type="pmid">19875703</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Jia</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride</article-title><source>Journal of Hepatology</source><volume>53</volume><fpage>934</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.05.018</pub-id><pub-id pub-id-type="pmid">20675007</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yi</surname><given-names>C-X</given-names></name><name><surname>Katiraei</surname><given-names>S</given-names></name><name><surname>Kooijman</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>E</given-names></name><name><surname>Chung</surname><given-names>CK</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>van den Heuvel</surname><given-names>JK</given-names></name><name><surname>Meijer</surname><given-names>OC</given-names></name><name><surname>Berbée</surname><given-names>JFP</given-names></name><name><surname>Heijink</surname><given-names>M</given-names></name><name><surname>Giera</surname><given-names>M</given-names></name><name><surname>Willems van Dijk</surname><given-names>K</given-names></name><name><surname>Groen</surname><given-names>AK</given-names></name><name><surname>Rensen</surname><given-names>PCN</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit</article-title><source>Gut</source><volume>67</volume><fpage>1269</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2017-314050</pub-id><pub-id pub-id-type="pmid">29101261</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Menke</surname><given-names>AL</given-names></name><name><surname>Driessen</surname><given-names>A</given-names></name><name><surname>Koek</surname><given-names>GH</given-names></name><name><surname>Lindeman</surname><given-names>JH</given-names></name><name><surname>Stoop</surname><given-names>R</given-names></name><name><surname>Havekes</surname><given-names>LM</given-names></name><name><surname>Kleemann</surname><given-names>R</given-names></name><name><surname>van den Hoek</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e115922</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0115922</pub-id><pub-id pub-id-type="pmid">25535951</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Lam</surname><given-names>KSL</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Hoo</surname><given-names>RCL</given-names></name><name><surname>Konishi</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Bornstein</surname><given-names>SR</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice</article-title><source>Cell Metabolism</source><volume>17</volume><fpage>779</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.04.005</pub-id><pub-id pub-id-type="pmid">23663741</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Schönke</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Kooijman</surname><given-names>S</given-names></name><name><surname>Boon</surname><given-names>MR</given-names></name><name><surname>Larsson</surname><given-names>M</given-names></name><name><surname>Wallenius</surname><given-names>K</given-names></name><name><surname>Dekker</surname><given-names>N</given-names></name><name><surname>Barlind</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>X-R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Rensen</surname><given-names>PCN</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis</article-title><source>Cardiovascular Research</source><volume>118</volume><fpage>489</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvab076</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Decato</surname><given-names>BE</given-names></name><name><surname>Charles</surname><given-names>ED</given-names></name><name><surname>Shevell</surname><given-names>DE</given-names></name><name><surname>McNaney</surname><given-names>C</given-names></name><name><surname>Shipkova</surname><given-names>P</given-names></name><name><surname>Apfel</surname><given-names>A</given-names></name><name><surname>Tirucherai</surname><given-names>GS</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis</article-title><source>JHEP Reports</source><volume>4</volume><elocation-id>100392</elocation-id><pub-id pub-id-type="doi">10.1016/j.jhepr.2021.100392</pub-id><pub-id pub-id-type="pmid">34977519</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>MV</given-names></name><name><surname>Diehl</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pathogenesis of nonalcoholic steatohepatitis</article-title><source>Gastroenterology</source><volume>150</volume><fpage>1769</fpage><lpage>1777</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.02.066</pub-id><pub-id pub-id-type="pmid">26928243</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markan</surname><given-names>KR</given-names></name><name><surname>Naber</surname><given-names>MC</given-names></name><name><surname>Ameka</surname><given-names>MK</given-names></name><name><surname>Anderegg</surname><given-names>MD</given-names></name><name><surname>Mangelsdorf</surname><given-names>DJ</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Potthoff</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding</article-title><source>Diabetes</source><volume>63</volume><fpage>4057</fpage><lpage>4063</lpage><pub-id pub-id-type="doi">10.2337/db14-0595</pub-id><pub-id pub-id-type="pmid">25008183</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Bialowas</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>LQ</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The mir-182-5p/FGF21/acetylcholine axis mediates the crosstalk between adipocytes and macrophages to promote beige fat thermogenesis</article-title><source>JCI Insight</source><volume>6</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.150249</pub-id><pub-id pub-id-type="pmid">34264867</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>MC</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Mulder</surname><given-names>P</given-names></name><name><surname>Verschuren</surname><given-names>L</given-names></name><name><surname>Pieterman</surname><given-names>E</given-names></name><name><surname>Toet</surname><given-names>K</given-names></name><name><surname>Heeringa</surname><given-names>P</given-names></name><name><surname>Wielinga</surname><given-names>PY</given-names></name><name><surname>Kooistra</surname><given-names>T</given-names></name><name><surname>Kleemann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE (∗) 3leiden mice</article-title><source>Journal of Hepatology</source><volume>62</volume><fpage>1180</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2014.12.011</pub-id><pub-id pub-id-type="pmid">25514555</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulder</surname><given-names>P</given-names></name><name><surname>Morrison</surname><given-names>MC</given-names></name><name><surname>Wielinga</surname><given-names>PY</given-names></name><name><surname>van Duyvenvoorde</surname><given-names>W</given-names></name><name><surname>Kooistra</surname><given-names>T</given-names></name><name><surname>Kleemann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-alcoholic steatohepatitis in obesity</article-title><source>International Journal of Obesity</source><volume>40</volume><fpage>675</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1038/ijo.2015.226</pub-id><pub-id pub-id-type="pmid">26499443</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musso</surname><given-names>G</given-names></name><name><surname>Gambino</surname><given-names>R</given-names></name><name><surname>Cassader</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)</article-title><source>Progress in Lipid Research</source><volume>48</volume><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.plipres.2008.08.001</pub-id><pub-id pub-id-type="pmid">18824034</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathwani</surname><given-names>AC</given-names></name><name><surname>Reiss</surname><given-names>U</given-names></name><name><surname>Tuddenham</surname><given-names>E</given-names></name><name><surname>Chowdary</surname><given-names>P</given-names></name><name><surname>McIntosh</surname><given-names>J</given-names></name><name><surname>Riddell</surname><given-names>A</given-names></name><name><surname>Pie</surname><given-names>J</given-names></name><name><surname>Mahlangu</surname><given-names>JN</given-names></name><name><surname>Recht</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>YM</given-names></name><name><surname>Halka</surname><given-names>KG</given-names></name><name><surname>Meagher</surname><given-names>MM</given-names></name><name><surname>Nienhuis</surname><given-names>AW</given-names></name><name><surname>Davidoff</surname><given-names>AM</given-names></name><name><surname>Mangles</surname><given-names>S</given-names></name><name><surname>Morton</surname><given-names>CL</given-names></name><name><surname>Junfang</surname><given-names>Z</given-names></name><name><surname>Radulescu</surname><given-names>VC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Adeno-associated mediated gene transfer for hemophilia B:8 year follow up and impact of removing “ empty viral particles” on safety and efficacy of gene transfer</article-title><source>Blood</source><volume>132</volume><elocation-id>491</elocation-id><pub-id pub-id-type="doi">10.1182/blood-2018-99-118334</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuschwander-Tetri</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites</article-title><source>Hepatology</source><volume>52</volume><fpage>774</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1002/hep.23719</pub-id><pub-id pub-id-type="pmid">20683968</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Nakatake</surname><given-names>Y</given-names></name><name><surname>Konishi</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Identification of a novel FGF, FGF-21, preferentially expressed in the liver</article-title><source>Biochimica et Biophysica Acta</source><volume>1492</volume><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/s0167-4781(00)00067-1</pub-id><pub-id pub-id-type="pmid">10858549</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>P</given-names></name><name><surname>Dobie</surname><given-names>R</given-names></name><name><surname>Wilson-Kanamori</surname><given-names>JR</given-names></name><name><surname>Dora</surname><given-names>EF</given-names></name><name><surname>Henderson</surname><given-names>BEP</given-names></name><name><surname>Luu</surname><given-names>NT</given-names></name><name><surname>Portman</surname><given-names>JR</given-names></name><name><surname>Matchett</surname><given-names>KP</given-names></name><name><surname>Brice</surname><given-names>M</given-names></name><name><surname>Marwick</surname><given-names>JA</given-names></name><name><surname>Taylor</surname><given-names>RS</given-names></name><name><surname>Efremova</surname><given-names>M</given-names></name><name><surname>Vento-Tormo</surname><given-names>R</given-names></name><name><surname>Carragher</surname><given-names>NO</given-names></name><name><surname>Kendall</surname><given-names>TJ</given-names></name><name><surname>Fallowfield</surname><given-names>JA</given-names></name><name><surname>Harrison</surname><given-names>EM</given-names></name><name><surname>Mole</surname><given-names>DJ</given-names></name><name><surname>Wigmore</surname><given-names>SJ</given-names></name><name><surname>Newsome</surname><given-names>PN</given-names></name><name><surname>Weston</surname><given-names>CJ</given-names></name><name><surname>Iredale</surname><given-names>JP</given-names></name><name><surname>Tacke</surname><given-names>F</given-names></name><name><surname>Pollard</surname><given-names>JW</given-names></name><name><surname>Ponting</surname><given-names>CP</given-names></name><name><surname>Marioni</surname><given-names>JC</given-names></name><name><surname>Teichmann</surname><given-names>SA</given-names></name><name><surname>Henderson</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Resolving the fibrotic niche of human liver cirrhosis at single-cell level</article-title><source>Nature</source><volume>575</volume><fpage>512</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1631-3</pub-id><pub-id pub-id-type="pmid">31597160</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ratziu</surname><given-names>V</given-names></name><name><surname>de Guevara</surname><given-names>L</given-names></name><name><surname>Safadi</surname><given-names>R</given-names></name><name><surname>Poordad</surname><given-names>F</given-names></name><name><surname>Fuster</surname><given-names>F</given-names></name><name><surname>Flores-Figueroa</surname><given-names>J</given-names></name><name><surname>Arrese</surname><given-names>M</given-names></name><name><surname>Fracanzani</surname><given-names>AL</given-names></name><name><surname>Ben Bashat</surname><given-names>D</given-names></name><name><surname>Lackner</surname><given-names>K</given-names></name><name><surname>Gorfine</surname><given-names>T</given-names></name><name><surname>Kadosh</surname><given-names>S</given-names></name><name><surname>Oren</surname><given-names>R</given-names></name><name><surname>Halperin</surname><given-names>M</given-names></name><name><surname>Hayardeny</surname><given-names>L</given-names></name><name><surname>Loomba</surname><given-names>R</given-names></name><name><surname>Friedman</surname><given-names>S</given-names></name><collab>ARREST investigator study group</collab><name><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2B trial</article-title><source>Nature Medicine</source><volume>27</volume><fpage>1825</fpage><lpage>1835</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01495-3</pub-id><pub-id pub-id-type="pmid">34621052</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remmerie</surname><given-names>A</given-names></name><name><surname>Martens</surname><given-names>L</given-names></name><name><surname>Thoné</surname><given-names>T</given-names></name><name><surname>Castoldi</surname><given-names>A</given-names></name><name><surname>Seurinck</surname><given-names>R</given-names></name><name><surname>Pavie</surname><given-names>B</given-names></name><name><surname>Roels</surname><given-names>J</given-names></name><name><surname>Vanneste</surname><given-names>B</given-names></name><name><surname>De Prijck</surname><given-names>S</given-names></name><name><surname>Vanhockerhout</surname><given-names>M</given-names></name><name><surname>Binte Abdul Latib</surname><given-names>M</given-names></name><name><surname>Devisscher</surname><given-names>L</given-names></name><name><surname>Hoorens</surname><given-names>A</given-names></name><name><surname>Bonnardel</surname><given-names>J</given-names></name><name><surname>Vandamme</surname><given-names>N</given-names></name><name><surname>Kremer</surname><given-names>A</given-names></name><name><surname>Borghgraef</surname><given-names>P</given-names></name><name><surname>Van Vlierberghe</surname><given-names>H</given-names></name><name><surname>Lippens</surname><given-names>S</given-names></name><name><surname>Pearce</surname><given-names>E</given-names></name><name><surname>Saeys</surname><given-names>Y</given-names></name><name><surname>Scott</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver</article-title><source>Immunity</source><volume>53</volume><fpage>641</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.08.004</pub-id><pub-id pub-id-type="pmid">32888418</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanyal</surname><given-names>A</given-names></name><name><surname>Charles</surname><given-names>ED</given-names></name><name><surname>Neuschwander-Tetri</surname><given-names>BA</given-names></name><name><surname>Loomba</surname><given-names>R</given-names></name><name><surname>Harrison</surname><given-names>SA</given-names></name><name><surname>Abdelmalek</surname><given-names>MF</given-names></name><name><surname>Lawitz</surname><given-names>EJ</given-names></name><name><surname>Halegoua-DeMarzio</surname><given-names>D</given-names></name><name><surname>Kundu</surname><given-names>S</given-names></name><name><surname>Noviello</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Christian</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pegbelfermin (BMS-986036), a pegylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2A trial</article-title><source>Lancet</source><volume>392</volume><fpage>2705</fpage><lpage>2717</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31785-9</pub-id><pub-id pub-id-type="pmid">30554783</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlein</surname><given-names>C</given-names></name><name><surname>Talukdar</surname><given-names>S</given-names></name><name><surname>Heine</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>AW</given-names></name><name><surname>Krott</surname><given-names>LM</given-names></name><name><surname>Nilsson</surname><given-names>SK</given-names></name><name><surname>Brenner</surname><given-names>MB</given-names></name><name><surname>Heeren</surname><given-names>J</given-names></name><name><surname>Scheja</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fgf21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues</article-title><source>Cell Metabolism</source><volume>23</volume><fpage>441</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.01.006</pub-id><pub-id pub-id-type="pmid">26853749</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwabe</surname><given-names>RF</given-names></name><name><surname>Tabas</surname><given-names>I</given-names></name><name><surname>Pajvani</surname><given-names>UB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanisms of fibrosis development in nonalcoholic steatohepatitis</article-title><source>Gastroenterology</source><volume>158</volume><fpage>1913</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.11.311</pub-id><pub-id pub-id-type="pmid">32044315</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidman</surname><given-names>JS</given-names></name><name><surname>Troutman</surname><given-names>TD</given-names></name><name><surname>Sakai</surname><given-names>M</given-names></name><name><surname>Gola</surname><given-names>A</given-names></name><name><surname>Spann</surname><given-names>NJ</given-names></name><name><surname>Bennett</surname><given-names>H</given-names></name><name><surname>Bruni</surname><given-names>CM</given-names></name><name><surname>Ouyang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>RZ</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Vu</surname><given-names>BT</given-names></name><name><surname>Pasillas</surname><given-names>MP</given-names></name><name><surname>Ego</surname><given-names>KM</given-names></name><name><surname>Gosselin</surname><given-names>D</given-names></name><name><surname>Link</surname><given-names>VM</given-names></name><name><surname>Chong</surname><given-names>L-W</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name><name><surname>Thompson</surname><given-names>BM</given-names></name><name><surname>McDonald</surname><given-names>JG</given-names></name><name><surname>Hosseini</surname><given-names>M</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name><name><surname>Germain</surname><given-names>RN</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis</article-title><source>Immunity</source><volume>52</volume><fpage>1057</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.04.001</pub-id><pub-id pub-id-type="pmid">32362324</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>Häring</surname><given-names>H-U</given-names></name><name><surname>Cusi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Non-Alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies</article-title><source>The Lancet. Diabetes &amp; Endocrinology</source><volume>7</volume><fpage>313</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(18)30154-2</pub-id><pub-id pub-id-type="pmid">30174213</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tacke</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting hepatic macrophages to treat liver diseases</article-title><source>Journal of Hepatology</source><volume>66</volume><fpage>1300</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2017.02.026</pub-id><pub-id pub-id-type="pmid">28267621</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>RS</given-names></name><name><surname>Taylor</surname><given-names>RJ</given-names></name><name><surname>Bayliss</surname><given-names>S</given-names></name><name><surname>Hagström</surname><given-names>H</given-names></name><name><surname>Nasr</surname><given-names>P</given-names></name><name><surname>Schattenberg</surname><given-names>JM</given-names></name><name><surname>Ishigami</surname><given-names>M</given-names></name><name><surname>Toyoda</surname><given-names>H</given-names></name><name><surname>Wai-Sun Wong</surname><given-names>V</given-names></name><name><surname>Peleg</surname><given-names>N</given-names></name><name><surname>Shlomai</surname><given-names>A</given-names></name><name><surname>Sebastiani</surname><given-names>G</given-names></name><name><surname>Seko</surname><given-names>Y</given-names></name><name><surname>Bhala</surname><given-names>N</given-names></name><name><surname>Younossi</surname><given-names>ZM</given-names></name><name><surname>Anstee</surname><given-names>QM</given-names></name><name><surname>McPherson</surname><given-names>S</given-names></name><name><surname>Newsome</surname><given-names>PN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis</article-title><source>Gastroenterology</source><volume>158</volume><fpage>1611</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.01.043</pub-id><pub-id pub-id-type="pmid">32027911</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>S</given-names></name><name><surname>Baba</surname><given-names>I</given-names></name><name><surname>Poupel</surname><given-names>L</given-names></name><name><surname>Dussaud</surname><given-names>S</given-names></name><name><surname>Moreau</surname><given-names>M</given-names></name><name><surname>Gélineau</surname><given-names>A</given-names></name><name><surname>Marcelin</surname><given-names>G</given-names></name><name><surname>Magréau-Davy</surname><given-names>E</given-names></name><name><surname>Ouhachi</surname><given-names>M</given-names></name><name><surname>Lesnik</surname><given-names>P</given-names></name><name><surname>Boissonnas</surname><given-names>A</given-names></name><name><surname>Le Goff</surname><given-names>W</given-names></name><name><surname>Clausen</surname><given-names>BE</given-names></name><name><surname>Yvan-Charvet</surname><given-names>L</given-names></name><name><surname>Sennlaub</surname><given-names>F</given-names></name><name><surname>Huby</surname><given-names>T</given-names></name><name><surname>Gautier</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis</article-title><source>Immunity</source><volume>53</volume><fpage>627</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.06.003</pub-id><pub-id pub-id-type="pmid">32562600</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>H</given-names></name><name><surname>Okamoto</surname><given-names>AY</given-names></name><name><surname>Shan</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Fxr, a bile acid receptor and biological sensor</article-title><source>Trends in Cardiovascular Medicine</source><volume>10</volume><fpage>30</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/s1050-1738(00)00043-8</pub-id><pub-id pub-id-type="pmid">11150726</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Hoek</surname><given-names>AM</given-names></name><name><surname>van der Hoorn</surname><given-names>JWA</given-names></name><name><surname>Maas</surname><given-names>AC</given-names></name><name><surname>van den Hoogen</surname><given-names>RM</given-names></name><name><surname>van Nieuwkoop</surname><given-names>A</given-names></name><name><surname>Droog</surname><given-names>S</given-names></name><name><surname>Offerman</surname><given-names>EH</given-names></name><name><surname>Pieterman</surname><given-names>EJ</given-names></name><name><surname>Havekes</surname><given-names>LM</given-names></name><name><surname>Princen</surname><given-names>HMG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome</article-title><source>Diabetes, Obesity &amp; Metabolism</source><volume>16</volume><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1111/dom.12252</pub-id><pub-id pub-id-type="pmid">24373179</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Hoorn</surname><given-names>JWA</given-names></name><name><surname>Jukema</surname><given-names>JW</given-names></name><name><surname>Havekes</surname><given-names>LM</given-names></name><name><surname>Lundholm</surname><given-names>E</given-names></name><name><surname>Camejo</surname><given-names>G</given-names></name><name><surname>Rensen</surname><given-names>PCN</given-names></name><name><surname>Princen</surname><given-names>HMG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3leiden.CETP transgenic mice</article-title><source>British Journal of Pharmacology</source><volume>156</volume><fpage>1067</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2008.00109.x</pub-id><pub-id pub-id-type="pmid">19220285</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Zande</surname><given-names>HJP</given-names></name><name><surname>Gonzalez</surname><given-names>MA</given-names></name><name><surname>de Ruiter</surname><given-names>K</given-names></name><name><surname>Wilbers</surname><given-names>RHP</given-names></name><name><surname>García-Tardón</surname><given-names>N</given-names></name><name><surname>van Huizen</surname><given-names>M</given-names></name><name><surname>van Noort</surname><given-names>K</given-names></name><name><surname>Pelgrom</surname><given-names>LR</given-names></name><name><surname>Lambooij</surname><given-names>JM</given-names></name><name><surname>Zawistowska-Deniziak</surname><given-names>A</given-names></name><name><surname>Otto</surname><given-names>F</given-names></name><name><surname>Ozir-Fazalalikhan</surname><given-names>A</given-names></name><name><surname>van Willigen</surname><given-names>D</given-names></name><name><surname>Welling</surname><given-names>M</given-names></name><name><surname>Poles</surname><given-names>J</given-names></name><name><surname>van Leeuwen</surname><given-names>F</given-names></name><name><surname>Hokke</surname><given-names>CH</given-names></name><name><surname>Schots</surname><given-names>A</given-names></name><name><surname>Yazdanbakhsh</surname><given-names>M</given-names></name><name><surname>Loke</surname><given-names>P</given-names></name><name><surname>Guigas</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The helminth glycoprotein omega-1 improves metabolic homeostasis in obese mice through type 2 immunity-independent inhibition of food intake</article-title><source>FASEB Journal</source><volume>35</volume><elocation-id>e21331</elocation-id><pub-id pub-id-type="doi">10.1096/fj.202001973R</pub-id><pub-id pub-id-type="pmid">33476078</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westerterp</surname><given-names>M</given-names></name><name><surname>van der Hoogt</surname><given-names>CC</given-names></name><name><surname>de Haan</surname><given-names>W</given-names></name><name><surname>Offerman</surname><given-names>EH</given-names></name><name><surname>Dallinga-Thie</surname><given-names>GM</given-names></name><name><surname>Jukema</surname><given-names>JW</given-names></name><name><surname>Havekes</surname><given-names>LM</given-names></name><name><surname>Rensen</surname><given-names>PCN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-leiden mice</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>26</volume><fpage>2552</fpage><lpage>2559</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000243925.65265.3c</pub-id><pub-id pub-id-type="pmid">16946130</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Vijayakumar</surname><given-names>A</given-names></name><name><surname>Kahn</surname><given-names>BB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Metabolites as regulators of insulin sensitivity and metabolism</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>19</volume><fpage>654</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1038/s41580-018-0044-8</pub-id><pub-id pub-id-type="pmid">30104701</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sting-Mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis</article-title><source>The Journal of Clinical Investigation</source><volume>129</volume><fpage>546</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1172/JCI121842</pub-id><pub-id pub-id-type="pmid">30561388</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarei</surname><given-names>M</given-names></name><name><surname>Pizarro-Delgado</surname><given-names>J</given-names></name><name><surname>Barroso</surname><given-names>E</given-names></name><name><surname>Palomer</surname><given-names>X</given-names></name><name><surname>Vázquez-Carrera</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeting FGF21 for the treatment of nonalcoholic steatohepatitis</article-title><source>Trends in Pharmacological Sciences</source><volume>41</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2019.12.005</pub-id><pub-id pub-id-type="pmid">31980251</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yeung</surname><given-names>DCY</given-names></name><name><surname>Karpisek</surname><given-names>M</given-names></name><name><surname>Stejskal</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>Z-G</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Wong</surname><given-names>RLC</given-names></name><name><surname>Chow</surname><given-names>W-S</given-names></name><name><surname>Tso</surname><given-names>AWK</given-names></name><name><surname>Lam</surname><given-names>KSL</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans</article-title><source>Diabetes</source><volume>57</volume><fpage>1246</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.2337/db07-1476</pub-id><pub-id pub-id-type="pmid">18252893</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Gupte</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Weiszmann</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>KJ</given-names></name><name><surname>Richards</surname><given-names>WG</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Chronic over-expression of fibroblast growth factor 21 increases bile acid biosynthesis by opposing FGF15/19 action</article-title><source>EBioMedicine</source><volume>15</volume><fpage>173</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2016.12.016</pub-id><pub-id pub-id-type="pmid">28041926</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Hao</surname><given-names>G</given-names></name><name><surname>Shao</surname><given-names>M</given-names></name><name><surname>Nham</surname><given-names>K</given-names></name><name><surname>An</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Kusminski</surname><given-names>CM</given-names></name><name><surname>Hassan</surname><given-names>G</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Zhai</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name><name><surname>Oz</surname><given-names>OK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An adipose tissue atlas: an image-guided identification of human-like bat and beige depots in rodents</article-title><source>Cell Metabolism</source><volume>27</volume><fpage>252</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.12.004</pub-id><pub-id pub-id-type="pmid">29320705</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Materials and methods</title><sec sec-type="appendix" id="s8-1"><title>Generation of recombinant AAV vectors</title><p>AD-293 cells (Agilent, Santa Clara, CA, USA) were plated in a five layered chamber in Gibco DMEM supplemented with 10% Gibco FBS and 1% Gibco penicillin-streptomycin (Thermo Fisher Scientific, Waltham, MA, USA). When these cells reached at 60–85% confluency under the microscope, they were transfected by polyethylenimine (Polyscience, Torrance, CA, USA) with triple plasmids, including pHelper containing adenoviral E2A and E4 genes, pRep2Cap8 encoding AAV2 Rep proteins and AAV8 serotype capsid, and either pAAV-apolipoprotein E (<italic>Apoe</italic>)/alpha-1-antitrypsin (<italic>Aat</italic>) promoter-driven codon-optimized murine <italic>Fgf21</italic> or pAAV-<italic>Apoe</italic>/no plasmid, in a ratio of 2:1.4:1, respectively. After 72 hr of the post-transfection, cells were harvested and lysed via three freeze-thaw cycles followed by 1 hr of benzonase treatment at 37°C. Supernatants were then further purified using iodixanol gradient-based ultracentrifugation. Titers of all AAV vectors used for in vivo study were quantitated by quantitative reverse transcriptase-PCR. Given that the AAV8 vector is naturally mouse hepatocyte trophic, the AAT promoter is highly active in hepatocytes, and hepatocytes have a slow turnover, this approach results in sustained hepatocyte-selective expression of murine <italic>Fgf21</italic> in the long term. Since the recombinant AAV8 vector was generated by a standard and helper-free 3 plasmid transfection system, this vector does not express AAV8 and adenoviral helper proteins, and cannot replicate in transduced hepatocytes. Pilot data in C57BL/6 mice showed that the AAV8-<italic>Fgf21</italic> vector (3×10<sup>10</sup>, 1×10<sup>11</sup>, and 1×10<sup>12</sup> genome copies/mouse) did not cause liver injury, as judged from unaffected alanine transaminase and aspartate transaminase levels in plasma at 8 days after injection.</p></sec><sec sec-type="appendix" id="s8-2"><title>Body weight and plasma glucose, TG and TC</title><p>Body weight (n=18 per group) was recorded weekly of all mice throughout the study. Every 4 weeks, mice were fasted for 4 hr (9.00–13.00), and subsequently, tail vein blood was collected into paraoxon-coated glass capillaries. Plasma (n=18 per group) was collected and measured for glucose, TG, and TC using commercial enzymatic kits (Roche Diagnostics, Mannheim, Germany).</p></sec><sec sec-type="appendix" id="s8-3"><title>Plasma FGF21, adiponectin, and lipoprotein profile</title><p>Plasma FGF21 concentrations were determined at week –1 (pooled samples, n=6 per group), week 4 (pooled samples, n=6 per group), and week 23 (n=12–16 per group) using Mouse/Rat FGF21 Quantikine ELISA Kit (R&amp;D Systems, Minneapolis, NE, USA). Plasma adiponectin levels were measured at week 22 (n=10 per group) using Mouse Adiponectin/Acrp30 Quantikine ELISA Kit (R&amp;D Systems, Minneapolis, NE, USA). At week 22, 4 µL of 4 hr fasting plasma per mouse (n=18 per group) were pooled in each treatment group to measure the distribution of TG and TC over lipoproteins by fast-performance liquid chromatography using Super 6 column (GE Healthcare, Piscataway, NJ, USA).</p></sec><sec sec-type="appendix" id="s8-4"><title>Glucose tolerance test and lipid tolerance test</title><p>At week 16, an IPGTT was performed with an injection of D-glucose (2 g/kg body weight) after 4 hr fasting (9.00–13.00; n=8 per group). Blood was collected via tail vein at 0, 5, 15, 30, 60, and 120 min for each test. The glucose was measured with a OneTouch Ultra glucometer (AccuCheck Sensor, Roche Diagnostics, Almere, The Netherlands), and the area under the curve was calculated. During IPGTT, extra blood was collected at 0 and 15 min, spun down, and the serum samples were stored at –20°C for glucose measurement using a commercial enzymatic kit (Roche Diagnostics; Mannheim, Germany) and insulin measurement using an Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem, Zaandam, The Netherlands). HOMA-IR (homeostasis model assessment of insulin resistance) was calculated with the following formula: [fasting serum glucose (mM)×fasting serum insulin (µU/mL)]/22.5 (<xref ref-type="bibr" rid="bib19">Fraulob et al., 2010</xref>). At week 20, oral lipid tolerance test was conducted. To this end, mice (n=10 per group) were fasted for 4 hr (9.00–13.00 hr), and received olive oil (10 mL/kg body weight) via oral gavage. Blood was collected into paraoxon-coated glass capillaries at 0, 2, 4, 6, and 8 hr, spun down, and the plasma samples were stored at –20°C for TG measurement using commercial enzymatic kits (Roche Diagnostics, Mannheim, Germany).</p></sec><sec sec-type="appendix" id="s8-5"><title>Hepatic lipids and hydroxyproline</title><p>Hepatic lipids were extracted from snap-frozen liver samples (n=18 per group) using a modified protocol from <xref ref-type="bibr" rid="bib9">Bligh and Dyer, 1959</xref>. Liver TG, TC and phospholipid (Instruchemie, Delfzijl, The Netherlands) and protein (Pierce, Thermo Fisher Scientific, Waltham, MA, USA) concentrations were measured. Hepatic lipids were expressed as nmol per mg protein. Hepatic hydroxyproline concentrations (n=18 per group) were determined using a Mouse Hydroxyproline Assay Kit (QuickZyme Biosciences, Leiden, The Netherlands).</p></sec><sec sec-type="appendix" id="s8-6"><title>Adipose tissue histology</title><p>Formalin-fixed paraffin-embedded iBAT, sWAT, and gWAT sections (5 µm thickness) were prepared for hematoxylin-eosin (H&amp;E) staining (<xref ref-type="bibr" rid="bib12">Cardiff et al., 2014</xref>). Moreover, iBAT and sWAT sections were processed for UCP-1 staining (<xref ref-type="bibr" rid="bib27">Kooijman et al., 2015</xref>), and gWAT sections were used for F4/80 staining (<xref ref-type="bibr" rid="bib30">Lanthier et al., 2010</xref>). The areas occupied by intracellular lipid vacuoles (n=18 per group) and UCP-1 (n=18 per group) were quantified using ImageJ software (version 1.52a; National Institutes of Health, Bethesda, MD, USA). Using ImageJ software, the size of adipocyte of gWAT (n=18 per group) and sWAT (n=18 per group) and the number of CLSs within the gWAT (n=18 per group) were assessed. The number of CLSs in the gWAT was expressed as the number of CLS per mm<sup>2</sup>.</p></sec><sec sec-type="appendix" id="s8-7"><title>Liver histology and histological grading of NAFLD activity score</title><p>Liver tissue (n=18 per group) was fixed, embedded, and sectioned (5 µm thickness) for H&amp;E, Oil Red O (ORO), F4/80, Picrosirius Red, and COL1A1 staining. The number of CLS in the liver was counted using ImageJ software and expressed as the number of CLS per mm<sup>2</sup>. In addition, hepatic collagen accumulation was evaluated by quantifying Picrosirius Red- and COL1A1-positive areas in the liver using ImageJ software. For NAFLD activity score determination, a clinically utilized scoring system was adapted for the current study based on liver section H&amp;E staining (<xref ref-type="bibr" rid="bib6">Bedossa et al., 2012</xref>). The scoring system is ranged from 0 to 7, and is evaluated semi-quantitatively through three criteria: steatosis (0–3), lobular inflammation (0–2), and hepatocellular ballooning (0–2). Values in figures for each staining present means of 6–9 different and randomly analyzed fields (~1.5 mm<sup>2</sup>) of each mouse, and were used for statistical analysis.</p></sec><sec sec-type="appendix" id="s8-8"><title>Gene expression analysis</title><p>Total RNA was isolated from snap-frozen tissues (n=18 per group for each tissue) using TriPure RNA Isolation Reagent (Roche Diagnostics, Mijdrecht, The Netherlands). Thereafter, complementary DNA for quantitative reverse transcriptase-PCR was generated using Moloney Murine Leukemia Virus Reverse Transcriptase (Promega, Leiden, The Netherlands). Then, mRNA expression was normalized to <italic>Actb</italic> and <italic>Rplp0</italic> mRNA levels and expressed as fold change compared with the LFCD group. The primer sequences are listed in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>.</p><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>List of polymerase chain reaction primer sequences used in mRNA expression analysis.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Gene</th><th align="left" valign="top">Forward primer (5’–3’)</th><th align="left" valign="top">Reverse primer (5’–3’)</th></tr></thead><tbody><tr><td align="left" valign="top"><italic>Abcg5</italic></td><td align="left" valign="top">GAGCTGCAGAGGATGATTGCT</td><td align="left" valign="top">AGCCACCCTGGTCTTGGA</td></tr><tr><td align="left" valign="top"><italic>Acta2</italic></td><td align="left" valign="top">CCTGACGGGCAGGTGATC</td><td align="left" valign="top">ATGAAAGATGGCTGGAAGAGAGTCT</td></tr><tr><td align="left" valign="top"><italic>Actb</italic></td><td align="left" valign="top">AACCGTGAAAAGATGACCCAGAT</td><td align="left" valign="top">CACAGCCTGGATGGCTACGTA</td></tr><tr><td align="left" valign="top"><italic>Adgre1</italic></td><td align="left" valign="top">CTTTGGCTATGGGCTTCCAGTC</td><td align="left" valign="top">GCAAGGAGGACAGAGTTTATCGTG</td></tr><tr><td align="left" valign="top"><italic>Adipoq</italic></td><td align="left" valign="top">CTCCACCCAAGGGAACTTGT</td><td align="left" valign="top">TAGGACCAAGAAGACCTGCATC</td></tr><tr><td align="left" valign="top"><italic>Apob</italic></td><td align="left" valign="top">GCCCATTGTGGACAAGTTGATC</td><td align="left" valign="top">CCAGGACTTGGAGGTCTTGGA</td></tr><tr><td align="left" valign="top"><italic>Ccl2</italic></td><td align="left" valign="top">GCATCTGCCCTAAGGTCTTCA</td><td align="left" valign="top">TTCACTGTCACACTGGTCACTCCTA</td></tr><tr><td align="left" valign="top"><italic>Cd36</italic></td><td align="left" valign="top">GCAAAGAACAGCAGCAAAATC</td><td align="left" valign="top">CAGTGAAGGCTCAAAGATGG</td></tr><tr><td align="left" valign="top"><italic>Col1a1</italic></td><td align="left" valign="top">GAGAGAGCATGACCGATGGATT</td><td align="left" valign="top">TGTAGGCTACGCTGTTCTTGCA</td></tr><tr><td align="left" valign="top"><italic>Cpt1a</italic></td><td align="left" valign="top">GAGACTTCCAACGCATGACA</td><td align="left" valign="top">ATGGGTTGGGGTGATGTAGA</td></tr><tr><td align="left" valign="top"><italic>Ctgf</italic></td><td align="left" valign="top">GGCCTCTTCTGCGATTTCG</td><td align="left" valign="top">CCATCTTTGGCAGTGCACACT</td></tr><tr><td align="left" valign="top"><italic>Cyp7a1</italic></td><td align="left" valign="top">CAGGGAGATGCTCTGTGTTCA</td><td align="left" valign="top">AGGCATACATCCCTTCCGTGA</td></tr><tr><td align="left" valign="top"><italic>Cyp8b1</italic></td><td align="left" valign="top">GGACAGCCTATCCTTGGTGA</td><td align="left" valign="top">CGGAACTTCCTGAACAGCTC</td></tr><tr><td align="left" valign="top"><italic>Cyp27a1</italic></td><td align="left" valign="top">TCTGGCTACCTGCACTTCCT</td><td align="left" valign="top">CTGGATCTCTGGGCTCTTTG</td></tr><tr><td align="left" valign="top"><italic>Codon-optimized Fgf21</italic></td><td align="left" valign="top">GCCCACCTGGAGATCAGGGAGGA</td><td align="left" valign="top">GGCAGGAAGCGCACAGGTCCCCAG</td></tr><tr><td align="left" valign="top"><italic>Fgf21</italic></td><td align="left" valign="top">GGGGTCATTCAAATCCTGGGTGTCA</td><td align="left" valign="top">ACACATTGTAACCGTCCTCCAGCAG</td></tr><tr><td align="left" valign="top"><italic>Fgfr1</italic></td><td align="left" valign="top">AGAGTCCAAGAGTAAAAGCAGC</td><td align="left" valign="top">CTTCCGAGGTTCAGCTCTCC</td></tr><tr><td align="left" valign="top"><italic>Fgfr2</italic></td><td align="left" valign="top">GCTATAAGGTACGAAACCAGCAC</td><td align="left" valign="top">GGTTGATGGACCCGTATTCATTC</td></tr><tr><td align="left" valign="top"><italic>Fgfr4</italic></td><td align="left" valign="top">TCCATGACCGTCGTACACAAT</td><td align="left" valign="top">ATTTGACAGTATTCCCGGCAG</td></tr><tr><td align="left" valign="top">Il1b</td><td align="left" valign="top">GCAACTGTTCCTGAACTCAACT</td><td align="left" valign="top">ATCTTTTGGGGTCCGTCAACT</td></tr><tr><td align="left" valign="top"><italic>Klb</italic></td><td align="left" valign="top">TGTTCTGCTGCGAGCTGTTAC</td><td align="left" valign="top">TACCGGACTCACGTACTGTTT</td></tr><tr><td align="left" valign="top"><italic>Mttp</italic></td><td align="left" valign="top">CTCTTGGCAGTGCTTTTTCTCT</td><td align="left" valign="top">GAGCTTGTATAGCCGCTCATT</td></tr><tr><td align="left" valign="top"><italic>Pgc1a</italic></td><td align="left" valign="top">TGCTAGCGGTTCTCACAGAG</td><td align="left" valign="top">AGTGCTAAGACCGCTGCATT</td></tr><tr><td align="left" valign="top"><italic>Ppara</italic></td><td align="left" valign="top">ATGCCAGTACTGCCGTTTTC</td><td align="left" valign="top">GGCCTTGACCTTGTTCATGT</td></tr><tr><td align="left" valign="top"><italic>Rplp0</italic></td><td align="left" valign="top">GGACCCGAGAAGACCTCCTT</td><td align="left" valign="top">GCACATCACTCAGAATTTCAATGG</td></tr><tr><td align="left" valign="top"><italic>Tgfb1</italic></td><td align="left" valign="top">TTGCCCTCTACAACCAACACAA</td><td align="left" valign="top">GGCTTGCGACCCACGTAGTA</td></tr><tr><td align="left" valign="top"><italic>Tnfa</italic></td><td align="left" valign="top">AGCCCACGTCGTAGCAAACCAC</td><td align="left" valign="top">TCGGGGCAGCCTTGTCCCTT</td></tr></tbody></table><table-wrap-foot><fn><p>Abcg5, ATP-binding cassette transporter G member 5; <italic>Acta2</italic>, actin α2; <italic>Actb</italic>, β-actin <italic>Adgre1</italic>, adhesion G protein-coupled receptor E1; <italic>Adipoq</italic>, adiponectin; <italic>Apob</italic>, apolipoprotein B; <italic>Ccl2</italic>, C–C motif chemokine ligand 2; <italic>Cd36</italic>, cluster of differentiation 36; <italic>Col1a1,</italic> collagen type 1α1; <italic>Cpt1a,</italic> carnitine palmitoyl transferase 1α; <italic>Ctgf</italic>, connective tissue growth factor; <italic>Cyp7a1</italic>, cholesterol 7α-hydroxylase; <italic>Cyp8b1</italic>, sterol 12α-hydroxylase; <italic>Cyp27a1,</italic> sterol 27-hydroxylase; <italic>Fgf21</italic>, exogenous fibroblast growth factor; <italic>Fgfr</italic>, fibroblast growth factor receptor; <italic>Il1b,</italic> interleukin-1β; <italic>Klb</italic>, β-Klotho; <italic>Pgc1a,</italic> peroxisome proliferator-activated receptor gamma coactivator 1α; <italic>Ppara,</italic> peroxisome proliferator-activated receptor α; <italic>Rplp0,</italic> ribosomal protein lateral stalk subunit p0; <italic>Tgfb1,</italic> transforming growth factor-β; <italic>Tnfa</italic>, tumor necrosis factor α.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="appendix" id="s8-9"><title>Isolation of hepatic leukocytes</title><p>At the end of the study, livers (n=5 per group) were collected in ice-cold RPMI 1640+Glutamax (Thermo Fisher Scientific, Waltham, MA, USA). The tissues were subsequently minced and digested for 45 min at 37°C in RPMI 1640+Glutamax supplemented with 1 mg/mL collagenase type IV from <italic>Clostridium histolyticum</italic> (Sigma-Aldrich, St Louis, MO, USA), 2000 U/mL DNase (Sigma-Aldrich, St Louis, MO, USA) and 1 mM CaCl<sub>2</sub> as previously described (<xref ref-type="bibr" rid="bib60">van der Zande et al., 2021</xref>). The digested liver tissues were passed through a 100 µm cell strainer and washed with PBS supplemented with 0.5% BSA and 2 mM EDTA (PBS/BSA/EDTA). The samples were spun down (530 × <italic>g</italic>, 10 min at 4°C) after which the pellet was resuspended in PBS/BSA/EDTA and centrifuged at 50 × <italic>g</italic> to pellet the hepatocytes (3 min at 4°C). The supernatant was next collected and centrifuged (530 × <italic>g</italic>, 10 min at 4°C) after which the pellet was treated with erythrocyte lysis buffer (0.15 M NH<sub>4</sub>Cl; 1 mM KHCO<sub>3</sub>; 0.1 mM Na<sub>2</sub>EDTA) for 2 min at room temperature. After washing with PBS/BSA/EDTA, total leukocytes were isolated by means of magnetic-activated cell sorting (MACS) using LS columns and CD45 MicroBeads (35 µL beads per liver; Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s protocol. Isolated CD45<sup>+</sup> cells were counted and stained with Zombie NIR (BioLegend, San Diego, CA, USA) for 20 min at room temperature followed by fixation with 1.9% paraformaldehyde (Sigma-Aldrich, St Louis, MO, USA) for 15 min at room temperature after which the fixed leukocytes were further processed for flow cytometry.</p></sec><sec sec-type="appendix" id="s8-10"><title>Flow cytometry</title><p>For analysis of hepatic leukocyte subsets, isolated CD45<sup>+</sup> cells were incubated with a cocktail of antibodies directed against XCR1, CD11c, CD19, Ly6G, F4/80, MHC-II, CD45, CLEC2, Siglec-F, CD64, CD8, NK1.1, CD11b, CD4, CD90.2, Ly6C, CD3, CD36, CD9, and TIM4 in PBS/BSA/EDTA supplemented with True-Stain monocyte blocker (BioLegend, San Diego, CA, USA) and Brilliant Stain Buffer Plus (BD Biosciences, Franklin Lakes, NJ, USA) for 30 min at 4°C. The stained samples (n=5 per group) were measured by spectral flow cytometry using a Cytek Aurora spectral flow cytometer (Cytek Biosciences, Fremont, CA, USA). Spectral unmixing of the flow cytometry data was performed using SpectroFlo v3.0 (Cytek Biosciences, Fremont, CA, USA). Gating of flow cytometry data was performed using FlowJo v10.8 Software (BD Biosciences, Franklin Lakes, NJ, USA). Dimensionality reduction by means of Uniform Manifold Approximation and Projection (UMAP) was performed using OMIQ data analysis software (Omiq Inc, Santa Clara, CA, USA). Statistical analysis was performed using GraphPad version 9.01 for Windows (GraphPad Software, La Jolla, CA, USA). Representative gating strategies are shown in <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref> and information regarding the antibodies used is listed in <xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>.</p><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>List of antibodies and other reagents used for flow cytometry analyses.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Target</th><th align="left" valign="top">Clone</th><th align="left" valign="top">Conjugate</th><th align="left" valign="top">Source</th><th align="left" valign="top">Catalog number</th></tr></thead><tbody><tr><td align="left" valign="top">CD3</td><td align="char" char="." valign="top">17A2</td><td align="left" valign="top">APC/Fire-810</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">100267</td></tr><tr><td align="left" valign="top">CD4</td><td align="left" valign="top">RM4-5</td><td align="left" valign="top">APC</td><td align="left" valign="top">eBioscience</td><td align="char" char="hyphen" valign="top">17-0042-83</td></tr><tr><td align="left" valign="top">CD8</td><td align="left" valign="top">RPA-T8</td><td align="left" valign="top">PE-Cy5</td><td align="left" valign="top">BD Biosciences</td><td align="char" char="." valign="top">561951</td></tr><tr><td align="left" valign="top">CD9</td><td align="left" valign="top">MZ3</td><td align="left" valign="top">PerCP-Cy5.5</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">124817</td></tr><tr><td align="left" valign="top">CD11b</td><td align="left" valign="top">M1/70</td><td align="left" valign="top">PE-Cy7</td><td align="left" valign="top">eBioscience</td><td align="char" char="hyphen" valign="top">25-0112-82</td></tr><tr><td align="left" valign="top">CD11c</td><td align="left" valign="top">HL3</td><td align="left" valign="top">V450</td><td align="left" valign="top">BD Biosciences</td><td align="char" char="." valign="top">560521</td></tr><tr><td align="left" valign="top">CD19</td><td align="char" char="." valign="top">1D3</td><td align="left" valign="top">BV480</td><td align="left" valign="top">BD Biosciences</td><td align="char" char="." valign="top">566107</td></tr><tr><td align="left" valign="top">CD36</td><td align="left" valign="top">HM36</td><td align="left" valign="top">PE</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">102606</td></tr><tr><td align="left" valign="top">CD45</td><td align="char" char="hyphen" valign="top">30-F11</td><td align="left" valign="top">BV785</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">103149</td></tr><tr><td align="left" valign="top">CD64</td><td align="left" valign="top">X54-5/7.1</td><td align="left" valign="top">PE-DAZZLE594</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">139320</td></tr><tr><td align="left" valign="top">CD90.2</td><td align="char" char="hyphen" valign="top">30-H12</td><td align="left" valign="top">Alexa Fluor 700</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">105319</td></tr><tr><td align="left" valign="top">CLEC2</td><td align="char" char="." valign="top">17D9</td><td align="left" valign="top">FITC</td><td align="left" valign="top">Bio-Rad</td><td align="left" valign="top">MCA5700</td></tr><tr><td align="left" valign="top">F4/80</td><td align="left" valign="top">BM8</td><td align="left" valign="top">BV711</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">123147</td></tr><tr><td align="left" valign="top">Ly6C</td><td align="left" valign="top">HK1.4</td><td align="left" valign="top">APC-Cy7</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">128025</td></tr><tr><td align="left" valign="top">Ly6G</td><td align="char" char="." valign="top">1A8</td><td align="left" valign="top">BV650</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">127641</td></tr><tr><td align="left" valign="top">MHC-II</td><td align="left" valign="top">M5/114.15.2</td><td align="left" valign="top">BV750</td><td align="left" valign="top">BD Biosciences</td><td align="char" char="." valign="top">747458</td></tr><tr><td align="left" valign="top">MHC-II</td><td align="left" valign="top">M5/114.15.2</td><td align="left" valign="top">Alexa Fluor 700</td><td align="left" valign="top">Thermo Fisher</td><td align="char" char="hyphen" valign="top">56-5321-82</td></tr><tr><td align="left" valign="top">NK1.1</td><td align="left" valign="top">PK136</td><td align="left" valign="top">PerCP-Cy5.5</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">108727</td></tr><tr><td align="left" valign="top">Siglec-F</td><td align="left" valign="top">E50-2440</td><td align="left" valign="top">PE</td><td align="left" valign="top">BD Biosciences</td><td align="char" char="." valign="top">552126</td></tr><tr><td align="left" valign="top">Siglec-F</td><td align="left" valign="top">E50-2440</td><td align="left" valign="top">BV605</td><td align="left" valign="top">BD Biosciences</td><td align="char" char="." valign="top">740388</td></tr><tr><td align="left" valign="top">TIM4</td><td align="char" char="." valign="top">54 (RMT4-54)</td><td align="left" valign="top">PerCP-eFluor710</td><td align="left" valign="top">Thermo Fisher</td><td align="char" char="hyphen" valign="top">46-5866-82</td></tr><tr><td align="left" valign="top">XCR1</td><td align="left" valign="top">ZET</td><td align="left" valign="top">BV421</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">148216</td></tr><tr><td align="left" valign="top" colspan="3"><bold>Other reagents</bold></td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top" colspan="3">Zombie NIR Fixable Viability Kit</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">423106</td></tr><tr><td align="left" valign="top" colspan="3">True-Stain Monocyte Blocker</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">426103</td></tr><tr><td align="left" valign="top" colspan="3">Brilliant Stain Buffer Plus</td><td align="left" valign="top">BD Biosciences</td><td align="char" char="." valign="top">566385</td></tr></tbody></table></table-wrap></sec></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83075.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mistry</surname><given-names>Pramod</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.09.20.508654" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.20.508654"/></front-stub><body><p>The study examines the mechanism of hepatic FGF21 using trangenic and over-expression models to show that it limits hepatic lipotoxicity, inflammation and fibrogenesis. They provide convincing data to support the notion that FGF21 blocks hepatic lipid influx and accumulation through combined endocrine and autocrine signaling, respectively, which prevent Kupffer cell activation, and scar-associated macrophages to inhibit fibrogenesis.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83075.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mistry</surname><given-names>Pramod</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.20.508654">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.09.20.508654v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) More information on the AAV construct is needed.</p><p>a. Is the sequence human or murine FGF21?</p><p>b. Does AAV mediate FGF21 expression in other liver cells, for instance endothelial or Kupffer cells?</p><p>c. What happens to the endogenous FGF21 mRNA upon the viral gain of function?</p><p>d. AAV usually allows an expression for up to 21-28 days; how did the authors manage to have such long persistence of the mRNA and protein expression?</p><p>e. Is this construct able to replicate in vivo?</p><p>f. Were serum ALT/AST sampled acutely post injections (time-course) during the pilot to find the best compromise between expression and cytotoxicity?</p><p>g. Any limitations of the AAV model should be discussed</p><p>2) Please provide a rationale as to why the 23-week time point was chosen, as it appears the FGF21 effect on weight and cardiometabolic parameters may have already occurred within the first few weeks of FGF21 overexpression. Also, were FGF21 levels assayed at any point between 4 weeks and 23 weeks?</p><p>3) FGF21 is considered a stress-induced hormone whose levels rise in situations of metabolic stress including diet-induced obesity and NASH. As such, one would expect to see some upregulation (even if mild) of FGF21 in HFCD mice (Figure 1A). How would the authors explain the lack of FGF21 upregulation?</p><p>4) Clarify the methods for histological analysis of the liver in Figure 4. It seems to be based on the SAF criteria, which should take discrete values of 0,1,2,3 for steatosis, 0,1,2 for inflammation, and 0,1,2 for ballooning. However, particularly for inflammation and ballooning, the values are clearly graded along the scale.</p><p>5) Given the differences in brown fat activity and physiology between mice and humans, it would be important for the authors to either moderate their comments on the UCP1 dependence of their phenotype or provide more data to clarify to what extent their findings are UCP1-dependent (e.g. food intake in the FGF21 overexpression model and/or evidence of increased energy expenditure).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83075.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential Revisions (for the authors):</p><p>1) More information on the AAV construct is needed.</p><p>a. Is the sequence human or murine FGF21?</p></disp-quote><p>The AAV8 vector used in the present study expresses codon-optimized murine <italic>Fgf21</italic> cDNA under the control of a strong liver-specific apolipoprotein E (<italic>Apoe</italic>)/α-1-antitrypsin (<italic>Aat</italic>) promoter. We have included the following text in the revised manuscript.</p><p>Materials and methods</p><p>Page 20 Line 450: “… expressing codon-optimized murine <italic>Fgf21</italic> …”</p><p>Supporting Material and Methods</p><p>Page 2 Lines 35-36: “…and either pAAV apolipoprotein E (<italic>Apoe</italic>)/α-1-antitrypsin (<italic>Aa</italic>t) promoter-driven codon-optimized murine <italic>Fgf21</italic> or…”</p><disp-quote content-type="editor-comment"><p>b. Does AAV mediate FGF21 expression in other liver cells, for instance endothelial or Kupffer cells?</p></disp-quote><p>As mentioned in our response to a, we used an AAV8-<italic>Apoe</italic>/<italic>Aat</italic> vector in this study. Given that the AAV8 vector is naturally mouse hepatocyte trophic, and <italic>Aat</italic> promoter is highly active in hepatocytes, this approach should result in hepatocyte-selective expression of murine FGF21. We have now included the following text (which also includes responses to other questions) in the Supporting Materials and methods.</p><p>Page 2 Lines 40-43: “Given that the AAV8 vector is naturally mouse hepatocyte trophic, the AAT promoter is highly active in hepatocytes, and hepatocytes have a slow turnover, this approach results in sustained hepatocyte-selective expression of murine <italic>Fgf21</italic> in the long-term.”</p><disp-quote content-type="editor-comment"><p>c. What happens to the endogenous FGF21 mRNA upon the viral gain of function?</p></disp-quote><p>Following the editors and reviewers’ comment on endogenous FGF21 mRNA expression, we have now measured hepatic endogenous <italic>Fgf21</italic> expression. We observed that HFCD feeding increased endogenous <italic>Fgf21</italic> expression, which was prevented by viral overexpression of codon-optimized murine FGF21 (new Figure 1B).</p><p>The new data and related descriptions have been included in the revised manuscript.</p><p>Results</p><p>Page 8 Lines 149-151: “In addition, we observed that HFCD feeding increased hepatic endogenous <italic>Fgf21</italic> expression (+184%), which, however, was prevented by AAV8-<italic>Fgf21</italic> administration (Figure 1B).”</p><disp-quote content-type="editor-comment"><p>d. AAV usually allows an expression for up to 21-28 days; how did the authors manage to have such long persistence of the mRNA and protein expression?</p></disp-quote><p>In non-dividing or slowly dividing cell types such as hepatocytes, AAV8 vectors do allow long-term transgene expression. In fact, upon liver-targeted AAV8-luciferase delivery to mice, we have seen sustained luciferase expression at least for 1 year. In fact, in a human hemophilia B gene therapy trial, AAV8 vector-mediated delivery of Factor IX resulted in stable Factor IX expression over a period of 8 years following systemic administration in patients [1]. We have now included the following text in the Supporting Materials and methods.</p><p>Page 2 Lines 42-43: “… hepatocytes have slow turnover, this approach results in sustained hepatocyte-selective expression of murine <italic>Fgf21</italic> in the long-term.”</p><disp-quote content-type="editor-comment"><p>e. Is this construct able to replicate in vivo?</p></disp-quote><p>The recombinant AAV8 vector was generated by a standard and helper-free 3 plasmid transfection system. Therefore, this vector does not express AAV8/adenoviral helper proteins, and cannot replicate in transduced hepatocytes. We have now added the following text in the Supporting Materials and methods.</p><p>Page 2 Lines 43-46: “Since the recombinant AAV8 vector was generated by a standard and helper-free 3 plasmid transfection system, this vector does not express AAV8/adenoviral helper proteins, and cannot replicate in transduced hepatocytes.”</p><disp-quote content-type="editor-comment"><p>f. Were serum ALT/AST sampled acutely post injections (time-course) during the pilot to find the best compromise between expression and cytotoxicity?</p></disp-quote><p>Before conducting the present study, we tested the acute effect of AAV8-FGF21 on plasma ALT and AST levels in high-fat diet (HFD)-fed wild-type mice after 8-days post the vector administration (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). As expected, plasma ALT and AST levels in mice of the HFD+PBS group were elevated when compared to those in the Chow group. However, as compared to the HFD+PBS group, we did not observe acute increases in plasma ALT and AST levels in mice of HFD+AAV8-FGF21 groups.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Acute effects of AAV8-FGF21 administration on plasma ALT/AST levels in mice.</title><p>C57BL/6 mice were fed a high-fat diet (HFD) for 40 weeks, after which these mice (n = 4-5) were treated with either PBS or various doses of AAV8-FGF21 vectors (3 × 10<sup>10</sup>, 1 × 10<sup>11</sup> and 1 × 10<sup>12</sup> genome copies/mouse). After 8 days of AAV8-FGF21 interventions, these mice were terminated, and plasma samples were collected for ALT and AST measurement. Data are shown as mean ± SD. Differences were assessed using one-way ANOVA followed by a Tukey post-test. ****P &lt; 0.0001, compared with the Chow group.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-sa2-fig1-v2.tif"/></fig><p>Therefore, these data indicate that the used dose of the vector in the present study does not induce acute liver injury.</p><p>We have now added the following text in the Supporting Materials and methods.</p><p>Page 2 Lines 46-49: “ Pilot data in C57BL/6 mice showed that the AAV8-<italic>Fgf21</italic> vector (3x10<sup>10</sup>, 1x10<sup>11</sup> and 1x10<sup>12</sup> genome copies/mouse) did not cause liver injury, as judged from unaffected alanine transaminase (ALT) and aspartate transaminase (AST) levels in plasma at 8 days after injection.”</p><disp-quote content-type="editor-comment"><p>g. Any limitations of the AAV model should be discussed</p></disp-quote><p>Following editors’ and reviewers’ comments, we have included the following text in the Discussion.</p><p>Page 18-19 Lines 417-427: “This study is not without limitations. In this work, we used a gene therapy approach to examine the effects of liver-derived FGF21 on NASH based on the use of a single injection of an AAV8 vector encoding codon-optimized murine FGF21. Although AAV8 is hepatocyte trophic, we have not excluded potential contribution of other hepatic cells to total FGF21 expression. Also, while AAV8-<italic>Fgf21</italic> was non-toxic, sustained supra-pharmacological plasma levels of FGF21 were achieved, which do not necessarily reflect effects of current pharmacological strategies with long-acting FGF21. Interestingly, AAV-mediated gene therapy has already been tested in the clinic for life-threatening diseases such as hemophilia B, and has demonstrated stable expression of factor IX following AAV-mediated delivery (59). Therefore, it is reasonable to speculate that liver-targeted gene therapy as an approach to induce stable overexpression of FGF21 may ultimately have potential to reach to the clinic.”</p><disp-quote content-type="editor-comment"><p>2) Please provide a rationale as to why the 23-week time point was chosen, as it appears the FGF21 effect on weight and cardiometabolic parameters may have already occurred within the first few weeks of FGF21 overexpression. Also, were FGF21 levels assayed at any point between 4 weeks and 23 weeks?</p></disp-quote><p>In the present study, we aimed to investigate the role of FGF21 in hepatic inflammation and early fibrosis in NASH development. Based on previous studies [2, 3] and a well-established protocol in our research group, we observed that upon the 23-week HFCD dietary intervention, APOE*3-Leiden.CETP mice exhibit hepatic inflammation and early fibrosis. We have now included the following text in the Materials and methods.</p><p>Page 20 Line 456-457: “…, at which APOE*3-Leiden.CETP mice have developed both steatosis, hepatic inflammation and early fibrosis (23, 61).”</p><p>As mentioned in (1), the AAV8 vector used here induces a long-lasting increase in FGF21 levels in the circulation. We therefore did not measure plasma FGF21 levels between weeks 4 and 23.</p><disp-quote content-type="editor-comment"><p>3) FGF21 is considered a stress-induced hormone whose levels rise in situations of metabolic stress including diet-induced obesity and NASH. As such, one would expect to see some upregulation (even if mild) of FGF21 in HFCD mice (Figure 1A). How would the authors explain the lack of FGF21 upregulation?</p></disp-quote><p>Although significant differences were not achieved using one-way ANOVA followed by a Tukey post-test, by performing a student <italic>t</italic>-test between the LFCD and HFCD groups, we did observe higher plasma FGF21 levels in the HFCD group compared to those of the LFCD group (see <xref ref-type="fig" rid="sa2fig2">Author response image 2A</xref>). We have also measured hepatic endogenous <italic>Fgf21</italic> expression (see response to comment 1c) to show that HFCD feeding did significantly increase the hepatic expression of endogenous <italic>Fgf21</italic>. Moreover, we showed that hepatic endogenous FGF21 expression was positively correlated with plasma endogenous FGF21 levels (see <xref ref-type="fig" rid="sa2fig2">Author response image 2B</xref>). Therefore, our data in fact are in agreement with previous studies showing increased FGF21 levels in patients with NASH and its associated metabolic disorders [4, 5].</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>HFCD increases endogenous FGF21 levels.</title><p>(A) Plasma endogenous FGF21 levels were measured before (at week -1; pooled samples, n = 6 per group) and after (at week 4, pooled samples, n = 6 per group; week 23, n = 12-16 per group) AAV8-null administration. (B) Plasma endogenous FGF21 levels (week 23) were plotted against the expression of hepatic endogenous FGF21 expression. Data are shown as mean ± SEM. (A) Differences were assessed using student t-test.(B) Linear regression analyses were performed.**P &lt; 0.01, compared with the LFCD group.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83075-sa2-fig2-v2.tif"/></fig><p>Results</p><p>Page 8 Line 151-156: “Furthermore, by performing a student <italic>t</italic>-test between the LFCD and HFCD groups, we did observe that as compared to the LFCD group, HFCD feeding increased plasma FGF21 levels at week 4 (+52%) and week 23 (+383%) (Figure 1C).These results are in agreement with previous findings showing that FGF21 is a stress-induced hepatokine whose levels increase in metabolically compromised states, such as obesity (16) and NAFLD (17).”</p><disp-quote content-type="editor-comment"><p>4) Clarify the methods for histological analysis of the liver in Figure 4. It seems to be based on the SAF criteria, which should take discrete values of 0,1,2,3 for steatosis, 0,1,2 for inflammation, and 0,1,2 for ballooning. However, particularly for inflammation and ballooning, the values are clearly graded along the scale.</p></disp-quote><p>We apologize this was not sufficiently clear. We have now included the following text in the Supporting Materials and methods.</p><p>Page 5 Lines 114-116: “Values in figures for each staining present means of 6-9 different and randomly analyzed fields (~1.5 mm<sup>2</sup>) of each mouse, and were used for statistical analysis.”</p><disp-quote content-type="editor-comment"><p>5) Given the differences in brown fat activity and physiology between mice and humans, it would be important for the authors to either moderate their comments on the UCP1 dependence of their phenotype or provide more data to clarify to what extent their findings are UCP1-dependent (e.g. food intake in the FGF21 overexpression model and/or evidence of increased energy expenditure).</p></disp-quote><p>Following editors’ and reviewers’ comments, we have edited and added the following text in the Discussion.</p><p>Page 16 Lines 355-360: “These data imply that FGF21 induces thermogenesis which increases energy expenditure, consistent with the thermogenic responses observed for recombinant FGF21 in C57BL/6 mice fed with an obesogenic diet (29). Likewise, by using APOE*3-Leiden.CETP mice, we previously reported that FGF21 treatment highly increased energy expenditure without affecting food intake (30).”</p><p>References:</p><p>1. Nathwani, A.C., et al., Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing &quot;Empty Viral Particles&quot; on Safety and Efficacy of Gene Transfer. Blood, 2018. 132.</p><p>2. Morrison, M.C., et al., Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE( *)3Leiden mice. J Hepatol, 2015. 62(5): p. 1180-6.</p><p>3. Hui, S.T., et al., The Genetic Architecture of Diet-Induced Hepatic Fibrosis in Mice. Hepatology, 2018. 68(6): p. 2182-2196.</p><p>4. Li, H., et al., Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol, 2010. 53(5): p. 934-40.</p><p>5. Dushay, J., et al., Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology, 2010. 139(2): p. 456-63.</p></body></sub-article></article>